Details of the Researcher

PHOTO

Shogo Shigeta
Section
Graduate School of Medicine
Job title
Associate Professor
Degree

  • 博士（医学）（東北大学）

Research History 8

  • 2024/04 - Present
    Tohoku University Graduate School of Medicine　Department of Gynecology　Associate Professor

  • 2023/01 - 2024/03
    Tohoku University School of Medicine　Department of Obstetrics and Gynecology

  • 2021/07 - 2022/12
    Tohoku University School of Medicine　Department of Obstetrics and Gynecology　Research Associate

  • 2020/08 - 2021/06
    Tohoku University Graduate School of Medicine　Department of Gynecology

  • 2019/01 - 2020/07
    Tohoku University Graduate School of Medicine　Deparmtent of Gynecology　Research Associate

  • 2016/09 - 2018/12
    Fred Hutchinson Cancer Research Center　Human Biology Division　Postdoctoral fellow

  • 2016/04 - 2016/08
    Tohoku University School of Medicine　Department of Obstetrics and Gynecology

  • 2012/04 - 2016/03
    Tohoku University Graduate School of Medicine　Department of Gynecology　Graduate student

Show all Show first 5

Education 2

  • Tohoku University Graduate School of Medicine　Department of Gynecology

    2012/04 - 2016/03

  • Tohoku University　School of Medicine

    1999/04 - 2006/03

Committee Memberships 6

  • 婦人科悪性腫瘍研究機構 (JGOG)　卵巣がん委員会 委員

    2023 - Present

  • 日本婦人科腫瘍学会　卵巣がん・卵管癌・腹膜癌治療ガイドライン2025年版 作成幹事

    2023 - 2025

  • 婦人科腫瘍学会 総務委員会　委員

    2022 - 2024

  • 日本婦人科腫瘍学会　子宮体がん治療ガイドライン2023年版 作成委員

    2021 - 2023

  • 日本婦人科腫瘍学会　子宮頸がん治療ガイドライン2022年版 作成委員

    2020 - 2022

  • 東北大学医学部　ヒトゲノム専門委員会

    2019/04 - 2020/07

Show all ︎Show first 5

Professional Memberships 7

  • Japan Society of Clinical Oncology

    2023/07 - Present

  • 日本婦人科病理学会

  • 日本ロボット外科学会

  • THE JAPANESE SOCIETY OF CLINICAL CYTOLOGY

  • JAPAN SOCIETY OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY AND MINIMALLY INVASIVE THERAPY

  • JAPAN SOCIETY OF GYNECOLOGIC ONCOLOGY

  • JAPAN SOCIETY OF OBSTETRICS AND GYNECOLOGY

︎Show all ︎Show first 5

Research Interests 3

  • Gynecologic malignancy

  • Precision medicine

  • Ovarian cancer

Research Areas 2

  • Life sciences / Tumor diagnostics and therapeutics / Gynecologic malignancy

  • Life sciences / Tumor diagnostics and therapeutics / Precision medicine

Awards 1

  1. Merit Award

    Asian Society of Gynecologic Oncology

Papers 69

  1. Breast cancer surveillance for epithelial ovarian cancer patients with BRCA1 and BRCA2 pathogenic variants: a single-center retrospective study. International-journal

    Junko Hasegawa-Minato, Mikako Tochigi, Shuko Miyahara, Kei Kudo, Yusuke Shibuya, Chiaki Hashimoto, Masumi Ishibashi, Shogo Shigeta, Hideki Tokunaga, Muneaki Shimada

    Japanese journal of clinical oncology　2025/01/21

    DOI： 10.1093/jjco/hyaf010 　

    More details Close

    OBJECTIVES: To identify a method for breast cancer (BC) surveillance in patients with epithelial ovarian cancer (EOC) with germline BRCA1/2 pathogenic variants (gBRCA1/2m) and the incidence of BC after EOC in the era of broad PARP inhibitors use. METHODS: We retrospectively analyzed the data on EOC patients who had gBRCA1/2m by genetic testing between January 2017 and August 2023 in our single center. RESULTS: Of 125 patients with EOC, 33 had gBRCA1/2m. Of these, 27 (81.8%) underwent BC surveillance, 20 ultrasound and/or mammography, and seven magnetic resonance imaging (MRI). The median time from EOC diagnosis to the initiation of BC surveillance was 8 months. EOC recurrence was significantly lower in the group with MRI than in the group without MRI (no case vs. 10 cases, P = .0261). The duration from EOC diagnosis to the start of BC surveillance was longer in the group with MRI than in the group without MRI (21 vs. 7 months, P = .1033). Two (6.1%) patients developed BC after EOC. Both cases were early stage, triple-negative BCs that occurred more than 3 years after the diagnosis of stage III EOC. CONCLUSIONS: With the advent of PARP inhibitors, long-term survival is expected to increase, and a certain number of patients with EOC after initial treatment may benefit from BC surveillance using MRI. In particular, BC surveillance with MRI may be considered for patients who have not experienced EOC recurrence for more than 2 years.

  2. Declining Prevalence of Human Papillomavirus Co-Infections Among Young Japanese Women With Cervical Cancer and Its Precursors. International-journal Peer-reviewed

    Eri Yoshiizumi, Mamiko Onuki, Iwao Kukimoto, Fumiaki Takahashi, Tomoya Matsui, Kyoko Hamasaki, Hiroyuki Kanao, Ai Nio, Hideaki Yahata, Mayuko Goda, Takanori Yokoyama, Tsuyoshi Hisa, Kazuto Tasaki, Yuri Tenjimbayashi, Haruya Saji, Wataru Kudaka, Yuji Takei, Shogo Shigeta, Takeshi Motohara, Hiroko Matsumiya, Keiichiro Nakamura, Hiroyuki Yoshida, Mitsuya Ishikawa, Junzo Hamanishi, Hidekatsu Nakai, Mayuyo Mori-Uchino, Yasuyuki Hirashima, Akihiko Sekizawa, Hiroyuki Yoshikawa, Nobuo Yaegashi, Koji Matsumoto

    Journal of medical virology　96　(12)　e70096　2024/12

    DOI： 10.1002/jmv.70096 　

    More details Close

    Co-infections with human papillomavirus (HPV) of multiple genotypes mainly occur due to increased sexual activity. To address the prevalence and trend of HPV co-infections in Japan, HPV-type-specific data from Japanese women (n = 8128) aged < 40 years and newly diagnosed with cervical abnormalities at 24 hospitals between 2012 and 2023 were analyzed. These included cervical intraepithelial neoplasia grade 1/2 (CIN1/2, n = 2745), CIN3/adenocarcinoma in situ (AIS) (n = 3953), and invasive cervical cancer (ICC, n = 1430). For women enrolled in this study since 2019, information on sexual behaviors was collected via a self-administered questionnaire. Time-trend analyses by disease category showed significant declines in the prevalence of multiple HPV infections in CIN1/2 (49.1%-38.3%, ptrend = 0.0004), CIN3/AIS (44.7%-31.5%, ptrend = 0.0002), and ICC (26.7%-10.5%, ptrend < 0.0001) during the last decade. When these data were analyzed separately for women aged 20-29 and 30-39 years, similar declining trends were observed in each disease category. Using data from 2111 women for whom information on sexual history was available, the number of sexual partners was strongly associated with increased multiple HPV infections (p < 0.0001). In conclusion, the declining prevalence of HPV co-infections in cervical cancer and its precursors may reflect a decrease in sexual activity among Japanese women of reproductive age.

  3. Comparison of Treatment Outcomes Between First-Line Chemotherapy With or Without Bevacizumab for Advanced Ovarian Clear Cell Carcinoma (Tohoku Gynecologic Cancer Unit: TGCU-RS001A Study) Peer-reviewed

    tadahiro shoji, Eriko Takatori, Takayuki Nagasawa, Masahiro Kagabu, Tsukasa BABA, Tatsuhiko Shigeto, Yukiko Matsumura, Dai Shimizu, Yukihiro Terada, Manabu Seino, Tsuyoshi Ohta, Satoru Nagase, Shogo Shigeta, Hideki Tokunaga, Muneaki Shimada, Michiko Kaiho-Sakuma, Shigenori Furukawa, Shu Soeda, Takafumi Watanabe, Fumiaki TAKAHASHI, Yoshihito Yokoyama

    Cancers　16　3801　2024/11

    DOI： 10.3390/cancers16223801 　

  4. 急速な肝不全の進行により救命困難であった多発肝転移を伴う臨床的絨毛癌の一例

    渡邊桜, 重田昌吾, 邑本美沙希, 太田真理子, 吉泉絵理, 湊純子, 橋本千明, 石橋ますみ, 島田宗昭, 齋藤昌利

    北日本産科婦人科学会総会・学術講演会プログラム・抄録集(Web)　71st　96-96　2024/09

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  5. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

    Nicoletta Colombo, Elena Biagioli, Kenichi Harano, Francesca Galli, Emma Hudson, Yoland Antill, Chel Hun Choi, Manuela Rabaglio, Frederic Marmé, Christian Marth, Gabriella Parma, Lorena Fariñas-Madrid, Shin Nishio, Karen Allan, Yeh Chen Lee, Elisa Piovano, Beatriz Pardo, Satoshi Nakagawa, John McQueen, Claudio Zamagni, Luis Manso, Kazuhiro Takehara, Giulia Tasca, Annamaria Ferrero, Germana Tognon, Andrea Alberto Lissoni, Mariacristina Petrella, Maria Elena Laudani, Eliana Rulli, Sara Uggeri, M. Pilar Barretina Ginesta, Paolo Zola, Claudia Casanova, Valentina Arcangeli, Lorenzo Antonuzzo, Angiolo Gadducci, Stefania Cosio, Andrew Clamp, Mojca Persic, Ian McNeish, Laura Tookman, Andrés Redondo Sanchez, Editta Baldini, Innocenza Palaia, Pierluigi Benedetti Panici, Nobutaka Takahashi, Janine Lombard, Antonio Ardizzoia, Alessandra Bologna, Ana Maria Herrero Ibáñez, Antonino Musolino, Raúl Márquez Vázquez, Klaus Pietzner, Elena Braicu, Viola A. Heinzelmann-Schwarz, Melanie Powell, Yoshihito Yokoyama, Sally Baron-Hay, Chiara Abeni, Cristina Martin Lorente, Juan Fernando Cueva, Fabian Trillsch, Florian Heitz, Beyhan Ataseven, Edgar Petru, Martin Leonhard Heubner, Azmat Hassanq Sadozye, Sidharth Dubey, Andrea Tazbirkova, Susan Tiley, Kathryn Chrystal, Sang Wun Kim, Mathias Fehr, Kate Scatchard, Anjana Anand, Alexandra Taylor, Hidemichi Watary, Takayuki Enomoto, Kosuke Yoshihara, Sudarsha Selva-Nayagam, Bhaskar Karki, Michelle Harrison, Kate Wilkinson, Jeffrey Goh, Amanda Glasgow, Lorraine Chantrill, Chulmin Lee, Alessandro Bertolini, Filomena Narducci, Giovanna Bellotti, Vittorio Fusco, Stefan Aebi, Maria Del Grande, Ilaria Colombo, Hideki Tokunaga, Shogo Shigeta, Geraldine Goss, Zhen Rong Siow, Christopher Steer, Hao Lin

    The Lancet Oncology　25　(9)　1135-1146　2024/09

    DOI： 10.1016/S1470-2045(24)00334-6 　

    ISSN： 1470-2045

    eISSN： 1474-5488

  6. Efficacy and safety of minimally invasive surgery versus open laparotomy for epithelial ovarian cancer: A systematic review and meta-analysis. International-journal Peer-reviewed

    Akira Yokoi, Hiroko Machida, Muneaki Shimada, Koji Mastuo, Shogo Shigeta, Shigenori Furukawa, Nobumichi Nishikawa, Hiroyuki Nomura, Kensuke Hori, Hideki Tokunaga, Tadahiro Shoji, Tsukasa Baba, Satoru Nagase

    Gynecologic oncology　190　42-52　2024/08/13

    DOI： 10.1016/j.ygyno.2024.08.011 　

    More details Close

    OBJECTIVE: To examine the efficacy and safety of minimally invasive surgery (MIS) and conventional abdominal surgery for epithelial ovarian cancer (EOC), stratified by treatment type. METHODS: A systematic review and meta-analysis were conducted by an Expert Panel of the Japan Society of Gynecologic Oncology Ovarian Cancer Committee. Several academic databases, including PubMed/MEDLINE, Cochrane Database, and Ichushi were searched by the Japan Medical Library Association on November 11, 2023, using the keywords "epithelial ovarian cancer", "minimally invasive surgery", "laparoscopic", and "robot-assisted". Articles describing MIS treatment for EOC compared with conventional abdominal surgery were independently assessed by two authors. The primary outcomes were survival and perioperative adverse events. RESULTS: After screening 1114 studies, 35 articles were identified, including primary staging surgery (PSS) for early-stage EOC EOC (n = 20) and neoadjuvant chemotherapy following interval debulking surgery (NACT-IDS; n = 10) and upfront primary debulking surgery (PDS; n = 5) for advanced-stage EOC. These studies included 29,888 patients (7661 undergoing MIS and 22,227 undergoing abdominal surgery). Patients receiving MIS and abdominal surgery had similar overall survival (PSS: odds ratio [OR] 1.02, 95% confidence interval [CI] 0.75-1.37; NACT-IDS: OR 0.93, 95%CI 0.25-3.44 and PDS: OR 0.66, 95%CI 0.36-1.22, all P > 0.05). MIS showed perioperative complication rates comparable to those of abdominal surgery (intraoperative and postoperative, all treatment types P ≥ 0.05). However, the rate of lymph node dissection in early-stage EOC (PSS: OR 0.49, 95%CI0.26-0.91) and multivisceral resections in advanced-stage EOC (NACT-IDS: OR 0.27 95%CI 0.16-0.44 and PDS: OR 0.27, 95%CI 0.16-0.44) was lower in MIS than in abdominal surgery (all P < 0.05). CONCLUSION: MIS did not negatively impact the survival and perioperative complications of patients with EOC compared to abdominal surgery. While MIS is a viable option, varied case selection and surgical procedures suggest potential bias, requiring further validation studies.

  7. Assessment of postoperative therapy de-escalation for early-stage, intermediate-risk cervical cancer. International-journal Peer-reviewed

    Koji Matsuo, Muneaki Shimada, Shinya Matsuzaki, Hiroko Machida, Shogo Shigeta, Hiroshi Yoshida, Kazuyoshi Kato, Hiroyuki Kanao, Munetaka Takekuma, Mikio Mikami, Aiko Okamoto

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society　2024/08/06

    DOI： 10.1136/ijgc-2024-005597 　

    More details Close

    OBJECTIVE: The objective of this study was to assess the oncologic outcome of surgically-treated patients with early-stage, intermediate-risk cervical cancer according to postoperative therapy modality. METHODS: This retrospective cohort study queried the Japanese Gynecologic Oncology Group's nationwide surgical data platform. The study population was 1084 patients with stage IB cervical cancer who underwent primary radical hysterectomy and lymphadenectomy from 2004 to 2008. Histology type-incorporated intermediate-risk factor patterns were clustered into three groups based on recurrence risk. Oncologic outcomes were assessed per postoperative therapy: external beam radiotherapy alone, concurrent chemo-radiotherapy, chemotherapy alone, and no treatment. RESULTS: Histology-incorporated intermediate-risk groups included: no lympho-vascular space invasion in any histology, or squamous cell carcinoma with lympho-vascular space invasion but no deep stromal invasion (n=559, 51.6%, group 1); squamous cell carcinoma with both lympho-vascular space invasion and deep cervical stromal invasion (n=281, 25.9%; group 2); and non-squamous histology with lympho-vascular space invasion (n=244, 22.5%; group 3). The 5-year disease-free survival rates were 93.3%, 89.3%, and 82.5% for group 1,-2, and -3, respectively (p<0.001), with group 3 exhibiting an almost three-fold increased recurrence risk compared with group 1 (adjusted-hazard ratio (aHR) 2.70, 95% confidence interval (CI) 1.70-4.32), followed by group 2 (aHR 1.67, 95% CI 1.01 to 2.75). Disease-free survival was similar across the postoperative therapy groups: 5 year rates for external beam radiotherapy alone, concurrent chemo-radiotherapy, chemotherapy alone, and no postoperative treatment, 94.8%, 87.2%, 93.6%, and 94.2% for group 1 (p=0.294); 85.0%, 93.3%, 87.3%, and 90.5% for group 2 (p=0.578); and 85.4%, 83.1%, 80.5%, and 83.3% for group 3 (p=0.876). The aHR for disease-free survival comparing no postoperative treatment to external beam radiotherapy alone was 1.10 (95% CI 0.37 to 3.28), 0.71 (95% CI 0.29 to 1.79), and 1.21 (95% CI 0.42 to 3.51) for group 1, group 2, and group 3, respectively. The observed exposure-outcome associations were similar for cause-specific survival (all, p>0.05). CONCLUSION: In this retrospective investigation in Japan, active surveillance without postoperative therapy following radical hysterectomy and lymphadenectomy was not associated with oncologic outcome in early-stage, intermediate-risk cervical cancer.

  8. 血漿メタボローム解析を用いた婦人科癌におけるバイオマーカーの探索

    菱沼 英史, 島田 宗昭, 松川 直美, 萩原 達也, 工藤 敬, 渋谷 祐介, 重田 昌吾, 元池 育子, 徳永 英樹, 木下 賢吾, 小柴 生造, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　252-252　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  9. 卵巣明細胞癌におけるゲノム情報と予後についての関連解析

    宮原 周子, 久木元 詩央香, 栃木 実佳子, 橋本 栄文, 萩原 達也, 清水 孝規, 遠藤 俊, 吉泉 絵理, 工藤 敬, 渋谷 祐介, 湊 純子, 岡村 容伸, 石橋 ますみ, 重田 昌吾, 徳永 英樹, 島田 宗昭

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　257-257　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  10. プラチナ感受性再発卵巣癌に対するPARP阻害剤再投与に関する検討

    吉泉 絵理, 重田 昌吾, 久木元 詩央香, 栃木 実佳子, 橋本 栄文, 萩原 達也, 遠藤 俊, 清水 孝規, 宮原 周子, 渋谷 祐介, 湊 純子, 石橋 ますみ, 橋本 千明, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　271-271　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  11. 組織型の確定診断に難渋した子宮癌肉腫

    石橋 ますみ, 宮原 周子, 渋谷 祐介, 湊 純子, 橋本 千明, 重田 昌吾, 徳永 英樹, 室山 佑希, 藤島 史喜, 島田 宗昭, 森谷 卓也

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　352-352　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  12. 一般住民コホート参加者に対する遺伝性乳がん卵巣がんの遺伝情報回付事業

    湊 純子, 島田 宗昭, 栃木 実佳子, 大根田 絹子, 濱中 洋平, 宮原 周子, 渋谷 祐介, 橋本 千明, 石橋 ますみ, 重田 昌吾, 徳永 英樹

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　332-332　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  13. 婦人科がんMISのnext innovation 卵巣がん手術における低侵襲手術の有効性と安全性 Systematic Reviewとメタ分析

    町田 弘子, 横井 暁, 島田 宗昭, 重田 昌吾, 古川 茂宜, 西川 伸道, 野村 弘行, 堀 謙輔, 徳永 英樹, 庄子 忠宏, 馬場 長, 永瀬 智

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　133-133　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  14. Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis. Peer-reviewed

    Mikako Tochigi, Shogo Shigeta, Muneaki Shimada, Shuko Miyahara, Junko Hasegawa-Minato, Yusuke Shibuya, Masumi Ishibashi, Chiaki Hashimoto, Hideki Tokunaga, Nobuo Yaegashi

    The Tohoku journal of experimental medicine　262　(2)　85-95　2024/02/27

    DOI： 10.1620/tjem.2023.J095 　

    More details Close

    A multi-kinase inhibitor, lenvatinib, plus an immune checkpoint inhibitor, pembrolizumab, became a viable therapeutic option for advanced or recurrent endometrial cancer in Japan by the end of 2021. The Japanese population has a relatively unique genetic background. Hence, the safety profile and effectiveness of lenvatinib plus pembrolizumab may differ between the Japanese and other populations. This single-center, retrospective study aimed to evaluate the treatment efficacy of lenvatinib plus pembrolizumab and the safety profile of the associated adverse events. The clinical records of 15 patients, who received lenvatinib plus pembrolizumab for advanced or recurrent endometrial cancer at the Tohoku University Hospital, were reviewed. Best overall response and disease control rates were 40.0% and 73.3%, respectively. Treatment was discontinued owing to disease progression and adverse events in six patients, respectively. As of the end of July 2023, treatment was ongoing in the remaining three patients. The median treatment and progression-free survival durations were 118 and 258 days, respectively. Relative dose intensity of lenvatinib was not positively associated with progression-free survival, neither during the first 4 weeks after treatment initiation nor during the entire treatment period. All patients experienced one or more adverse events, the most common of which were hypothyroidism (90%) and hypertension (83.3%). Among the 15 patients, 13 required lenvatinib dose reduction owing to adverse events. One patient developed grade 4 interstitial pneumonia requiring intensive care. Our results validate the short-term efficacy of lenvatinib plus pembrolizumab, and indicate that dose optimization of lenvatinib could be individualized without impairing efficacy.

  15. Long-Term and Short-Interval Assessment of Self-Reported Urinary and Sexual Functions after Nerve-Sparing Radical Hysterectomy: A Prospective Cohort Study. Peer-reviewed

    Masumi Ishibashi, Hitoshi Niikura, Motoko Ishida, Noriyuki Iwama, Hirohito Metoki, Shogo Shigeta, Tomoyuki Nagai, Hideki Tokunaga, Muneaki Shimada, Nobuo Yaegashi

    The Tohoku journal of experimental medicine　2024/02/08

    DOI： 10.1620/tjem.2024.J014 　

  16. ExcLAMation marks in a pelvic lymph node. International-journal Peer-reviewed

    Yuki Muroyama, Chihiro Inoue, Fumiyoshi Fujishima, Shogo Shigeta, Junko Hasegawa-Minato, Muneaki Shimada, Takashi Suzuki

    Clinical case reports　11　(12)　e8339　2023/12

    DOI： 10.1002/ccr3.8339 　

    More details Close

    Extrapulmonary lymphangioleiomyomatosis (LAM) can present as incidental nodal LAM in gynecological surgery specimens, that warrants systemic investigation and follow-up of concurrent and subsequent development of pulmonary and extrapulmonary LAM.

  17. An Attempt to Develop a New Treatment Strategy for Rare Refractory Gynecological Malignancies: The Japanese Gynecologic Oncology Group. Peer-reviewed

    Shogo Shigeta, Muneaki Shimada, Shiro Suzuki, Hiroaki Kajiyama, Katsutoshi Oda, Kazuhiro Takehara, Masaki Mandai, Daisuke Aoki, Takayuki Enomoto, Aikou Okamoto

    JMA journal　6　(4)　527-531　2023/10/16

    DOI： 10.31662/jmaj.2023-0024 　

    More details Close

    Platinum-based combination chemotherapy has been a frontline therapeutic strategy for advanced ovarian cancer. Although patients with ovarian high-grade serous carcinoma (HGSC) respond well to the combination therapy, those with relatively rare histologic subtypes, such as mucinous or clear cell carcinoma of the ovary (OCCC), show resistance to platinum-based chemotherapy. Even with the recently developed maintenance therapies using molecular targeted inhibitors for ovarian cancers, such as bevacizumab or poly (ADP-ribose) polymerase (PARP) inhibitors, the prognosis of non-HGSC ovarian cancers is unsatisfactory. To overcome the limitations in the treatment of rare ovarian cancers, the Japanese Gynecologic Oncology Group (JGOG) has launched a comprehensive project utilizing publicly available genomic databases, including a national clinico-genomic database maintained by the Center for Cancer Genomics and Advanced Therapeutics (C-CAT). JGOG, a leading group in Japan that conducts clinical trials for the treatment of gynecological malignancies, also established a nationwide network through the long-standing efforts of all participants. Currently, JGOG is engaged in a phase II international clinical trial (CYH33-G201: jRCT2031210216), targeting OCCC with PIK3CA hotspot mutations. The CYH33-G201 trial is sponsor-initiated, and JGOG, in collaboration with pharmaceutical companies, is actively recruiting participants. To expand the functions of the nationwide network that JGOG had already established, we held explanatory meetings for this clinical trial in nine different areas throughout Japan to promote the penetration of the CYH33-G201 trial. Through C-CAT database analysis, we estimated that approximately 40% of the patients with OCCC harbored at least 1 of the 17 PIK3CA hotspot mutations designated in the CYH33-G201 trial. JGOG will continue the challenge of establishing novel treatment strategies for rare refractory cancers that will benefit patients suffering from gynecological malignancies, especially those who do not receive satisfactory standard treatment and care.

  18. A qualitative systematic review of the significance of adjuvant therapy in patients with low-risk endometrial cancer presenting positive peritoneal cytology: a relevant study to the guideline update for endometrial cancer by the Japan society of gynecologic oncology guideline committee. International-journal Peer-reviewed

    Shogo Shigeta, Yosuke Konno, Yoshito Terai, Tohru Morisada, Hideki Tokunaga, Tsukasa Baba, Yoichi Kobayashi, Satoru Nagase

    Japanese journal of clinical oncology　2023/10/11

    DOI： 10.1093/jjco/hyad140 　

    More details Close

    In association with an update of the Japan Society of Gynecologic Oncology clinical practice guidelines for endometrial cancer in 2023, a systematic review was conducted about the therapeutic benefit of adjuvant therapy on patients with early-stage endometrial carcinoma, who presented positive peritoneal cytology (PPC) without the risk factors for recurrence. The systematic review only included two eligible retrospective studies. Both studies included patients with risk factors for recurrence. A nationwide study in the United States reported that adjuvant chemotherapy was associated with the reduced risk of death among patients with stages I-II endometrial cancer with PPC by multivariate, propensity score-adjusted analysis. Another single-center study in Japan reported no association between adjuvant chemotherapy and relapse-free survival among patients with stage IA endometrial cancer by univariate analysis. This systematic review identified that evidence was limited with conflicting results. Continuous evaluation is warranted to address this clinical question.

  19. Identification of predictive biomarkers for endometrial cancer diagnosis and treatment response monitoring using plasma metabolome profiling Peer-reviewed

    Eiji Hishinuma, Muneaki Shimada, Naomi Matsukawa, Yoshiko Shima, Bin Li, Ikuko N. Motoike, Yusuke Shibuya, Tatsuya Hagihara, Shogo Shigeta, Hideki Tokunaga, Daisuke Saigusa, Kengo Kinoshita, Seizo Koshiba, Nobuo Yaegashi

    Cancer &amp; Metabolism　11　(1)　2023/10/11

    Publisher: Springer Science and Business Media LLC

    DOI： 10.1186/s40170-023-00317-z 　

    eISSN： 2049-3002

    More details Close

    Abstract Background Endometrial cancer (EMC) is the most common female genital tract malignancy with an increasing prevalence in many countries including Japan, a fact that renders early detection and treatment necessary to protect health and fertility. Although early detection and treatment are necessary to further improve the prognosis of women with endometrial cancer, biomarkers that accurately reflect the pathophysiology of EMC patients are still unclear. Therefore, it is clinically critical to identify biomarkers to assess diagnosis and treatment efficacy to facilitate appropriate treatment and development of new therapies for EMC. Methods In this study, wide-targeted plasma metabolome analysis was performed to identify biomarkers for EMC diagnosis and the prediction of treatment responses. The absolute quantification of 628 metabolites in plasma samples from 142 patients with EMC was performed using ultra-high-performance liquid chromatography with tandem mass spectrometry. Results The concentrations of 111 metabolites increased significantly, while the concentrations of 148 metabolites decreased significantly in patients with EMC compared to healthy controls. Specifically, LysoPC and TGs, including unsaturated fatty acids, were reduced in patients with stage IA EMC compared to healthy controls, indicating that these metabolic profiles could be used as early diagnostic markers of EMC. In contrast, blood levels of amino acids such as histidine and tryptophan decreased as the risk of recurrence increased and the stages of EMC advanced. Furthermore, a marked increase in total TG and a decrease in specific TGs and free fatty acids including polyunsaturated fatty acids levels were observed in patients with EMC. These results suggest that the polyunsaturated fatty acids in patients with EMC are crucial for disease progression. Conclusions Our data identified specific metabolite profiles that reflect the pathogenesis of EMC and showed that these metabolites correlate with the risk of recurrence and disease stage. Analysis of changes in plasma metabolite profiles could be applied for the early diagnosis and monitoring of the course of treatment of EMC patients.

  20. Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study. International-journal Peer-reviewed

    Mamiko Onuki, Fumiaki Takahashi, Takashi Iwata, Hiroshi Nakazawa, Hideaki Yahata, Hiroyuki Kanao, Koji Horie, Katsuyuki Konnai, Ai Nio, Kazuhiro Takehara, Shoji Kamiura, Naotake Tsuda, Yuji Takei, Shogo Shigeta, Noriomi Matsumura, Hiroyuki Yoshida, Takeshi Motohara, Hiroyuki Yamazaki, Keiichiro Nakamura, Junzo Hamanishi, Nobutaka Tasaka, Mitsuya Ishikawa, Yasuyuki Hirashima, Wataru Kudaka, Mayuyo Mori-Uchino, Iwao Kukimoto, Takuma Fujii, Yoh Watanabe, Kiichiro Noda, Hiroyuki Yoshikawa, Nobuo Yaegashi, Koji Matsumoto

    Cancer science　114　(11)　4426-4432　2023/09/08

    DOI： 10.1111/cas.15943 　

    More details Close

    The first prophylactic vaccine against human papillomavirus (HPV) 16 and HPV18 was licensed in Japan in 2009. HPV vaccine effectiveness against high-grade cervical lesions has been demonstrated among young Japanese women, but evidence of its effects on invasive cervical cancer (ICC) is lacking. Using data from two different cancer registries, we compared recent trends of new ICC cases by age group using Poisson regression analysis. We also analyzed time trends in HPV16/18 prevalence among 1414 Japanese women aged <40 years newly diagnosed with ICC in the past decade. Based on the population-based cancer registry, the incidence of ICC among young women aged 20-29 years showed a significant decline from 3.6 to 2.8 per 100 000 women-years during 2016-2019, but no similar decline was observed for older age groups (p < 0.01). Similarly, using data from the gynecological cancer registry of the Japan Society of Obstetrics and Gynecology, the annual number of ICCs among women aged 20-29 years also decreased from 256 cases to 135 cases during 2011-2020 (p < 0.0001). Furthermore, a declining trend in HPV16/18 prevalence in ICC was observed only among women aged 20-29 years during 2017-2022 (90.5%-64.7%, p = 0.05; Cochran-Armitage trend test). This is the first report to suggest population-level effects of HPV vaccination on ICC in Japan. Although the declining trend in HPV16/18 prevalence among young women with ICC supports a causal linkage between vaccination and results from cancer registries, further studies are warranted to confirm that our findings are attributable to vaccination.

  21. Diagnostic Performance of Preoperative Imaging in Endometrial Cancer. International-journal Peer-reviewed

    Chiaki Hashimoto, Shogo Shigeta, Muneaki Shimada, Yusuke Shibuya, Masumi Ishibashi, Sakiko Kageyama, Tomomi Sato, Hideki Tokunaga, Kei Takase, Nobuo Yaegashi

    Current oncology (Toronto, Ont.)　30　(9)　8233-8244　2023/09/06

    DOI： 10.3390/curroncol30090597 　

    More details Close

    BACKGROUND: Endometrial cancer is one of the most common gynecological malignancies. Because the findings mentioned in radiogram interpretation reports issued by diagnostic radiologists influence treatment strategies, we aimed to evaluate the diagnostic accuracy of preoperative computed tomography (CT) and magnetic resonance imaging (MRI) interpretation results in clinically relevant settings. METHODS: The clinical records of patients diagnosed with endometrial cancer treated at Tohoku University Hospital from January 2012 to December 2021 were reviewed. The preoperative and pathologically estimated cancer stages were compared based on the results mentioned in the radiogram interpretation report. RESULTS: The preoperative and postoperative cancer stages were concordant in 70.0% of the patients. By contrast, the cancer stage was underdiagnosed and overdiagnosed in 21.7% and 8.2% of the patients, respectively. The sensitivities of MRI for deep myometrial invasion, cervical stromal invasion, vaginal invasion, and adnexal metastasis were 65.1%, 58.2%, 33.3%, and 18.4%, respectively. The sensitivity and specificity for pelvic lymph node metastasis using a combination of CT and MRI were 40.9% and 98.4%, respectively. Those for para-aortic lymph node metastases using CT were 37.0% and 99.5%, respectively. CONCLUSIONS: The low sensitivity observed in this study clarified the limitations of preoperative diagnostic performance in current clinical practice.

  22. Surgically treated cervical cancer in a high-risk group in the era of the 2018 FIGO staging schema: a nationwide study. International-journal Peer-reviewed

    Shogo Shigeta, Muneaki Shimada, Keita Tsuji, Zen Watanabe, Yasuhito Tanase, Koji Matsuo, Toru Nakanishi, Toshiaki Saito, Daisuke Aoki, Mikio Mikami

    Scientific reports　13　(1)　12020-12020　2023/07/25

    DOI： 10.1038/s41598-023-39014-8 　

    More details Close

    The 2018 International Federation of Gynecology and Obstetrics (FIGO) revision to the staging criteria for uterine cervical cancer adopted pathological staging for patients who underwent surgery. We investigated the correlation between clinicopathological factors and prognosis in patients with high-risk factors in accordance with the FIGO 2018 staging criteria by analyzing a real-world database of 6,192 patients who underwent radical hysterectomy at 116 institutions belonging to the Japan Gynecologic Oncology Group. A total of 1,392 patients were categorized into the high-risk group. Non-squamous cell carcinoma histology, regional lymph node metastasis, pT2 classification, and ovarian metastasis were identified as independent risk factors for mortality. Based on pathological findings, 313, 1003, and 76 patients were re-classified into FIGO 2018 stages IIB, IIIC1p, and IIIC2p, respectively. Patients with stage IIIC2p disease showed worse prognoses than those with stage IIB or IIIC1p disease. In patients with stage IIIC1p disease, overall survival was significantly better if their tumors were localized in the uterine cervix, except for single lymph node metastasis, with a 5-year overall survival rate of 91.8%. This study clarified the heterogeneity of the high-risk group and provided insights into the feasibility of upfront radical hysterectomy for a limited number of patients harboring high-risk factors.

  23. Assessing the Significance of Lymphadenectomy in Older Patients with Stage I Endometrial Cancer: A Single-Center, Retrospective Cohort Study. Peer-reviewed

    Junko Hasegawa-Minato, Shogo Shigeta, Muneaki Shimada, Masumi Ishibashi, Chiaki Hashimoto, Yusuke Shibuya, Tomoyuki Nagai, Hideki Tokunaga, Hitoshi Niikura, Nobuo Yaegashi

    The Tohoku journal of experimental medicine　2023/07/06

    DOI： 10.1620/tjem.2023.J055 　

  24. Identification of predictive biomarkers for diagnosis and radiation sensitivity of uterine cervical cancer using wide-targeted metabolomics. International-journal Peer-reviewed

    Eiji Hishinuma, Muneaki Shimada, Naomi Matsukawa, Bin Li, Ikuko N Motoike, Tatsuya Hagihara, Shogo Shigeta, Hideki Tokunaga, Daisuke Saigusa, Kengo Kinoshita, Seizo Koshiba, Nobuo Yaegashi

    The journal of obstetrics and gynaecology research　49　(8)　2109-2117　2023/06/09

    Publisher: Wiley

    DOI： 10.1111/jog.15709 　

    ISSN： 1341-8076

    eISSN： 1447-0756

    More details Close

    AIM: Uterine cervical cancer (UCC) is the fourth most common cancer in women, responsible for more than 300 000 deaths worldwide. Its early detection, by cervical cytology, and prevention, by vaccinating against human papilloma virus, greatly contribute to reducing cervical cancer mortality in women. However, penetration of the effective prevention of UCC in Japan remains low. Plasma metabolome analysis is widely used for biomarker discovery and the identification of cancer-specific metabolic pathways. Here, we aimed to identify predictive biomarkers for the diagnosis and radiation sensitivity of UCC using wide-targeted plasma metabolomics. METHODS: We analyzed 628 metabolites in plasma samples obtained from 45 patients with UCC using ultra-high-performance liquid chromatography with tandem mass spectrometry. RESULTS: The levels of 47 metabolites were significantly increased and those of 75 metabolites were significantly decreased in patients with UCC relative to healthy controls. Increased levels of arginine and ceramides, and decreased levels of tryptophan, ornithine, glycosylceramides, lysophosphatidylcholine, and phosphatidylcholine were characteristic of patients with UCC. Comparison of metabolite profiles in groups susceptible and non-susceptible to radiation therapy, a treatment for UCC, revealed marked variations in polyunsaturated fatty acid, nucleic acid, and arginine metabolism in the group not susceptible to treatment. CONCLUSIONS: Our findings suggest that the metabolite profile of patients with UCC may be an important indicator for distinguishing these patients from healthy cohorts, and may also be useful for predicting sensitivity to radiotherapy.

  25. Precautions during Direct Oral Anticoagulant Introduction in Gynecologic Malignancies: A Single-Center Retrospective Cohort Study Peer-reviewed

    Takanori Shimizu, Noriyuki Iwama, Hideki Tokunaga, Shun Endo, Shuko Miyahara, Asami Toki, Zen Watanabe, Junko Minato, Chiaki Hashimoto, Masumi Ishibashi, Shogo Shigeta, Muneaki Shimada, Nobuo Yaegashi

    Cancers　2023/02/10

    DOI： 10.3390/cancers15041132 　

  26. Retrospective analysis of local recurrence pattern by computed tomography image-guided intracavitary and interstitial brachytherapy for locally advanced cervical cancer in a single Japanese institution. International-journal Peer-reviewed

    Rei Umezawa, Hideki Tokunaga, Takaya Yamamoto, Shogo Shigeta, Noriyoshi Takahashi, Kazuya Takeda, Yu Suzuki, Keita Kishida, Kengo Ito, Noriyuki Kadoya, Muneaki Shimada, Keiichi Jingu

    Brachytherapy　22　(4)　477-486　2023

    DOI： 10.1016/j.brachy.2023.04.008 　

    More details Close

    PURPOSE: The purpose of this study was to investigate the treatment results with focus on local control (LC) by computed tomography (CT)-guided intracavity brachytherapy and interstitial brachytherapy (ICBT/ISBT) for locally advanced cervical cancer (LACC). METHODS AND MATERIALS: Patients with LACC undergoing ICBT/ISBT at least once in our institution between January 2017 and June 2019 were analyzed retrospectively. The primary endpoint was local control (LC), and the secondary endpoints were progression-free survival (PFS), overall survival (OS), and late toxicities. Differences between patient subgroups for prognostic factors in LC, PFS, and OS were analyzed using the log-rank test. The recurrence patterns of LC were also investigated. RESULTS: Forty-four patients were included in the present study. The median high-risk clinical target volume (HR-CTV) at the initial brachytherapy was 48.2 cc. The median total dose of HR-CTV D90 (EQD2) was 70.7 Gy. The median followup period was 39.4 months. The 3-year LC, PFS and OS rates in all patients were 88.2%, 56.6%, and 65.4% (95% CI 50.3-78.0%), respectively. Corpus invasion and large HR-CTV (70 cc or more) were significant prognostic factors in LC, PFS, and OS. Marginal recurrences at the fundus of the uterus were detected in 3 of 5 patients in whom local recurrence was observed. Late toxicities of Grade 3 or higher were detected in 3 patients (6.8%). CONCLUSIONS: Favorable LC was achieved by performing CT-guided ICBT/ISBT for LACC. The brachytherapy strategy for patients with corpus invasion or large HR-CTV may need to be reconsidered.

  27. Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study) Peer-reviewed

    Tadahiro Shoji, Eriko Takatori, Takayuki Nagasawa, Masahiro Kagabu, Tsukasa Baba, Tatsuhiko Shigeto, Yukiko Matsumura, Dai Shimizu, Yukihiro Terada, Manabu Seino, Tsuyoshi Ohta, Satoru Nagase, Shogo Shigeta, Hideki Tokunaga, Muneaki Shimada, Michiko Kaiho-Sakuma, Shigenori Furukawa, Shu Soeda, Takafumi Watanabe, Fumiaki Takahashi, Yoshihito Yokoyama

    International Journal of Clinical Oncology　27　(12)　1874-1880　2022/12

    Publisher: Springer Science and Business Media LLC

    DOI： 10.1007/s10147-022-02246-1 　

    ISSN： 1341-9625

    eISSN： 1437-7772

  28. Correction to: Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group.

    Shogo Shigeta, Muneaki Shimada, Keita Tsuji, Tomoyuki Nagai, Yasuhito Tanase, Koji Matsuo, Shoji Kamiura, Takashi Iwata, Harushige Yokota, Mikio Mikami

    International journal of clinical oncology　27　(9)　1516-1516　2022/09

    DOI： 10.1007/s10147-022-02211-y 　

  29. Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group. Peer-reviewed

    Shogo Shigeta, Muneaki Shimada, Keita Tsuji, Tomoyuki Nagai, Yasuhito Tanase, Koji Matsuo, Shoji Kamiura, Takashi Iwata, Harushige Yokota, Mikio Mikami

    International journal of clinical oncology　27　(9)　1507-1515　2022/09

    DOI： 10.1007/s10147-022-02198-6 　

    More details Close

    BACKGROUND: Adjuvant therapy is usually considered for surgically treated patients with uterine cervical cancer harboring intermediate risk (IR) factors such as large tumor diameter, stromal invasion to the outer half, and lymphovascular space invasion (LVSI). However, the indications and types of adjuvant therapy for the IR group remain controversial. This study aimed to analyze the differences in patient outcomes in the IR group to provide novel insights for tailoring adjuvant therapy. METHODS: Data from 6192 patients with cervical cancer who underwent radical hysterectomy at 116 institutions belonging to the Japanese Gynecologic Oncology Group were reviewed. RESULTS: In total, 1688 patients were classified into the IR group, of whom 37.3% did not receive adjuvant therapy. Conversely, approximately equal proportions of the remaining patients received adjuvant radiotherapy, concurrent chemoradiotherapy, and chemotherapy. Patients with all three risk factors showed worse overall survival than those with one or two risk factors. In addition to LVSI, non-squamous cell carcinoma histology, and vaginal invasion were identified as independent risk factors for both recurrence and mortality in multivariate analyses. Tumor diameter greater than 40 mm and surgical center volume were identified as independent risk factors for recurrence. Stromal invasion to the outer half and ovarian metastasis were identified as independent risk factors for mortality. CONCLUSIONS: This study revealed the significant differences in prognosis in the IR group. The indications for adjuvant therapy should be further studied, focusing on conventional risk factors and other pathological findings.

  30. A Retrospective Analysis of Clinical Biomarkers for Olaparib Maintenance Therapy in Patients with Recurrent Ovarian Cancer. Peer-reviewed

    Shun Endo, Shogo Shigeta, Hideki Tokunaga, Takanori Shimizu, Junko Hasegawa-Minato, Chiaki Hashimoto, Masumi Ishibashi, Tomoyuki Nagai, Naomi Shiga, Muneaki Shimada, Nobuo Yaegashi

    The Tohoku journal of experimental medicine　258　(1)　1-9　2022/08/05

    DOI： 10.1620/tjem.2022.J050 　

    More details Close

    Poly(ADP-ribose) polymerase (PARP) inhibitors theoretically promote synthetic lethality in cancer cells with homologous recombination deficiency (HRD). However, clinical evidence indicates that PARP inhibitors are also effective for treating HRD-negative ovarian cancer. The PARP inhibitor olaparib became available in Japan as a maintenance therapy for platinum-sensitive recurrent ovarian cancer regardless of homologous recombination status in April 2018. The purpose of this study was to identify potential clinical biomarkers for olaparib sensitivity in patients with recurrent ovarian cancer. Clinical information about the patients with recurrent ovarian cancer treated with olaparib maintenance therapy (OMT) was retrospectively collected. OMT duration was used as an indicator for olaparib sensitivity. The relationship between OMT duration and clinical parameters was statistically analyzed. We found a positive correlation between OMT duration and progression-free survival (PFS) or treatment free interval (TFI). In some cases, OMT duration exceeded PFS before olaparib introduction. We also found that more than half of the patients with measurable target lesions at the time of OMT introduction showed partial or complete response to OMT. These results validated the effectiveness of OMT and identified PFS and TFI as potential clinical markers for olaparib sensitivity in the patients with recurrent ovarian cancer.

  31. Prognostic factors of 2018 FIGO stage IB-IIA cervical cancer with absence of high/ intermediate surgical-pathological risk factors. International-journal Peer-reviewed

    Yusuke Shibuya, Muneaki Shimada, Keita Tsuji, Shogo Shigeta, Yasuhito Tanase, Koji Matsuo, Satoshi Yamaguchi, Hiroyuki Kanao, Toshiaki Saito, Mikio Mikami

    Japanese journal of clinical oncology　52　(11)　1289-1296　2022/08/01

    DOI： 10.1093/jjco/hyac125 　

    More details Close

    OBJECTIVE: This retrospective analysis of a real-world database of open radical hysterectomy in Japan aimed to reveal the clinicopathological findings and clinical outcomes of low-risk patients with stage IB-IIA cervical cancer. METHODS: A total of 1143 stage IB1, IB2 and IIA1 (reclassified by FIGO 2018 staging system) patients with cervical cancer who underwent radical hysterectomy between January 2004 and December 2008 from the Japanese Gynecologic Oncology Group database were analyzed. Low-risk patients were defined as those without a tumor size exceeding 4 cm, parametrial tumor involvement, deep (outer half) stromal invasion, lymphovascular space invasion or lymph nodal metastasis. RESULTS: 61.2% (772/1262) patients with stage IB1, 32.1% (229/932) with stage IB2 and 16.9% (72/294) of stage IIA1 were classified into the low-risk group. The 5-year overall survival and disease-free survival rates were 98.4 and 93.7%, respectively. Histological classification did not affect the survival rates, but stage IIA cases had significantly lower overall survival and disease-free survival (83.5 and 93.8%, respectively) than stage IB cases. The independent prognostic factors for disease-free survival were older age (≧50), histology, clinical stage and clinical stage as independent prognostic factors for overall survival. Regarding recurrence, older age, non-SCC and stage IIA1 were independent risk factors for local recurrence, but stage IIA1 was the only independent risk factor for distant metastasis. CONCLUSION: We found that stage IIA1 was the strongest risk factor for survival and recurrence of low-risk uterine cervical cancer (FIGO, 2018). In low-risk cases, stage IIA1 should be considered separately from stage IB.

  32. 当院における子宮筋腫に対する子宮動脈塞栓術(UAE)の治療効果の検討 Peer-reviewed

    佐藤 壮樹, 田邉 康次郎, 重田 昌吾, 力丸 裕哉, 新倉 仁

    産科と婦人科　89　(3)　309-315　2022/03

    Publisher: (株)診断と治療社

    ISSN： 0386-9792

  33. MicroRNA-152 Regulates Endometrial Serous Carcinoma Cell Motility by Suppressing Matrix Metalloproteinase 10 Expression. Peer-reviewed

    Shogo Shigeta, Yoh Watanabe, Fumihiko Suzuki, Satoru Nagase, Yusuke Shibuya, Masumi Ishibashi, Tomoyuki Nagai, Naomi Shiga, Masafumi Toyoshima, Hideki Tokunaga, Muneaki Shimada, Nobuo Yaegashi

    The Tohoku journal of experimental medicine　256　(3)　249-258　2022/03

    DOI： 10.1620/tjem.256.249 　

    More details Close

    MicroRNA-152 (miR-152) expression has been reported to be associated with poor prognosis in patients with endometrial serous carcinoma (ESC). However, the function of miR-152 in ESCs is not fully understood. The present study aimed to investigate the involvement of miR-152 in ESC progression. The influence of miR-152 overexpression on cell proliferation and motility was assessed by transfecting two human ESC cell lines, USPC-1 and SPAC-1-L, with a miR-152 precursor. MiR-152 overexpression increased apoptosis and inhibited the proliferation of the two ESC cell lines. Cell motility was also suppressed in both cell lines following precursor transfection. Conversely, miR-152 inhibitor transfection led to an increase in cell migration ability, suggesting the involvement of miR-152 in ESC cell motility. Results of the analysis of publicly available messenger RNA dataset indicated that high expression of matrix metalloproteinase 10 (MMP10), one of the predicted targets of miR-152 by microRNA target prediction database, was a poor prognostic factor for ESC. In vitro examination results revealed that miR-152 overexpression reduced MMP10 expression, and knockdown of MMP10 significantly reduced cell motility. This study elucidates the function of miR-152 as a tumor suppressor in ESCs. We demonstrated that miR-152 plays an important role in ESC cell motility by regulating MMP10 expression.

  34. Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program International-journal Peer-reviewed

    Mamiko Onuki, Kasumi Yamamoto, Hideaki Yahata, Hiroyuki Kanao, Koji Horie, Katsuyuki Konnai, Ai Nio, Kazuhiro Takehara, Shoji Kamiura, Naotake Tsuda, Yuji Takei, Shogo Shigeta, Hidekatsu Nakai, Hiroyuki Yoshida, Takeshi Motohara, Tatsuya Kato, Keiichiro Nakamura, Junzo Hamanishi, Nobutaka Tasaka, Mitsuya Ishikawa, Nobuhiro Kado, Yusuke Taira, Mayuyo Mori, Takashi Iwata, Fumiaki Takahashi, Iwao Kukimoto, Hiroyuki Yoshikawa, Nobuo Yaegashi, Koji Matsumoto

    Vaccines　10　(2)　188-188　2022/01/25

    Publisher: MDPI AG

    DOI： 10.3390/vaccines10020188 　

    eISSN： 2076-393X

    More details Close

    Since the human papillomavirus (HPV) vaccination program for Japanese girls aged 12–16 years began in 2010, vaccination uptake has been low in women born before 1993 but high (approximately 70%) in those born during 1994–1999. We previously compared the prevalence of vaccine types HPV16 and HPV18 in cervical intraepithelial neoplasia grade 1–3 (CIN1–3) or adenocarcinoma in situ (AIS) between vaccinated and unvaccinated cohorts and found direct protection effects among vaccinated women in Japan. In this study, we focused on changes in HPV16/18 prevalence among “unvaccinated” cohorts with CIN/AIS. We analyzed HPV16/18 prevalence among 5051 unvaccinated women aged &lt;40 years, newly diagnosed with CIN/AIS during 2012–2021 for time trends. Declining trends in HPV16/18 prevalence over 9 years were observed in CIN1 (36.0–10.0%, Ptrend = 0.03) and CIN2–3/AIS (62.5–36.4%, Ptrend = 0.07) among women aged &lt;25 years. HPV16/18 prevalence in CIN1 and CIN2–3/AIS diagnosed at age 20–24 years was lower in 1994–1999 birth cohorts compared with 1988–1993 birth cohorts (4.5% vs. 25.7% for CIN1 and 40.0% vs. 58.1% for CIN2–3/AIS, both p = 0.04). Significant reduction in HPV16/18 prevalence among young unvaccinated women with CIN1 and CIN2–3/AIS suggests herd effects of HPV vaccination in Japan.

  35. HPV vaccine effectiveness by age at first vaccination among Japanese women. International-journal Peer-reviewed

    Mamiko Onuki, Kasumi Yamamoto, Hideaki Yahata, Hiroyuki Kanao, Harushige Yokota, Hisamori Kato, Kumi Shimamoto, Kazuhiro Takehara, Shoji Kamiura, Naotake Tsuda, Yuji Takei, Shogo Shigeta, Noriomi Matsumura, Hiroyuki Yoshida, Takeshi Motohara, Hidemichi Watari, Keiichiro Nakamura, Akihiko Ueda, Nobutaka Tasaka, Mitsuya Ishikawa, Yasuyuki Hirashima, Wataru Kudaka, Ayumi Taguchi, Takashi Iwata, Fumiaki Takahashi, Iwao Kukimoto, Hiroyuki Yoshikawa, Nobuo Yaegashi, Koji Matsumoto

    Cancer science　113　(4)　1428-1434　2022/01/18

    DOI： 10.1111/cas.15270 　

    More details Close

    In Japan, the National Immunization Program against human papillomavirus (HPV) targets girls aged 12-16 years, and catch-up vaccination is recommended for young women up to age 26 years. Because HPV infection rates increase soon after sexual debut, we evaluated HPV vaccine effectiveness by age at first vaccination. Along with vaccination history, HPV genotyping results from 5795 women younger than 40 years diagnosed with cervical intraepithelial neoplasia grade 2-3 (CIN2-3), adenocarcinoma in situ (AIS) or invasive cervical cancer were analyzed. The attribution of vaccine-targeted types HPV16 or HPV18 to CIN2-3/AIS was 47.0% for unvaccinated women (n=4297), but 0.0%, 13.0%, 35.7% and 39.6% for women vaccinated at ages 12-15 years (n=36), 16-18 years (n=23), 19-22 years (n=14) and >22 years (n=91), respectively, indicating the greater effectiveness of HPV vaccination among those initiating vaccination at age ≤18 years (P<0.001). This finding was supported by age at first sexual intercourse; among women with ≥CIN2, only 9.6% were sexually active by age 14, but the percentage quickly increased to 48.1% by age 16 and 77.9% by age 18. Additionally, the HPV16/18 prevalence in CIN2-3/AIS was 0.0%, 12.5% and 40.0% for women vaccinated before (n=16), within 3 years (n=8) and >3 years after (n=15) first intercourse, respectively (P=0.003). In conclusion, our data appear to support routine HPV vaccination for girls aged 12-14 years and catch-up vaccination for adolescents aged ≤18 years in Japan.

  36. Rethinking the significance of surgery for uterine cervical cancer. International-journal Peer-reviewed

    Muneaki Shimada, Keita Tsuji, Shogo Shigeta, Tomoyuki Nagai, Zen Watanabe, Hideki Tokunaga, Junzo Kigawa, Nobuo Yaegashi

    The journal of obstetrics and gynaecology research　48　(3)　576-586　2021/12/14

    DOI： 10.1111/jog.15112 　

    More details Close

    BACKGROUND: Treatment strategies based on histological subtypes are unestablished. AIMS: Rethinking the significance of surgery for uterine cervical cancer. METHODS: Using the database of cervical cancer stages IB-IIB with extensive hysterectomy (Federation of Gynecology and Obstetrics [FIGO] 2008) established by the Japanese Gynecologic Oncology Group network, we conducted a clinicopathological study of cervical cancer cases reclassified according to the FIGO 2018 staging. In stage IB (FIGO 2018) cervical cancer patients, there was no significant difference in treatment outcome according to histological type, but in stages IIA, IIB, and IIIC1 (FIGO 2018), the treatment outcome of nonsquamous cell carcinoma was significantly worse than that of squamous cell carcinoma. Considering post-treatment health care, it is important to consider ovarian preservation in young patients with cervical cancer, up to stage IIA (FIGO 2018) for squamous cell carcinoma and stage IB1 (FIGO 2018) for nonsquamous cell carcinoma, after careful evaluation of clinicopathological factors before surgery. DISCUSSION: Locally advanced adenocarcinoma of the cervix is a rare and refractory cancer that has been shown to have low radiosensitivity, and its treatment outcome is still unsatisfactory. A new therapeutic strategy involving multidisciplinary treatment in combination with perioperative chemotherapy at a facility that can provide highly curative surgical treatment is desired. CONCLUSION: Minimally invasive surgery is being introduced for the treatment of early-stage cervical cancer. However, the number of eligible cases should be expanded in a phased manner, based on an objective evaluation of surgical outcomes at the facilities. Omics analysis may be useful to develop a new treatment for human papillomavirus nonrelated cervical cancer, represented by gastric mucinous carcinoma.

  37. Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125. International-journal Peer-reviewed

    Takamichi Minato, Shin Ito, Bin Li, Haruna Fujimori, Mai Mochizuki, Kazunori Yamaguchi, Keiichi Tamai, Muneaki Shimada, Hideki Tokunaga, Shogo Shigeta, Ikuro Sato, Hiroshi Shima, Hidekazu Yamada, Nobuo Yaegashi, Jun Yasuda

    Gynecologic oncology reports　38　100847-100847　2021/11

    DOI： 10.1016/j.gore.2021.100847 　

    More details Close

    Objective: Ovarian cancer (OC) is an intractable gynecological tumor, and frequent recurrence is experienced within a few years even after the complete eradication of tumor tissues by radical resection and neo-adjuvant chemotherapies. The conventional recurrence marker, CA125, is widely used for follow-up after resection of OC, but CA125 has a long half-life in blood and lacks dynamic responses to tumor recurrence. Recent developments in liquid biopsy procedures are expected to overcome the difficulties in early diagnosis of OC recurrence after surgery. Methods: We applied droplet digital PCR (ddPCR) technology to detect circulating tumor-derived DNA in OC patients' plasma during follow-up. Exome sequencing of 11 tumor-normal pairs of genomic DNA from consecutive OC patients identified tumor-specific mutations, and ddPCR probes were selected for each sample. Results: Six of 11 cases showed apparent recurrence during follow-up (mean progression-free survival was 348.3 days) and all six cases were positive in ddPCR analyses. In addition, ddPCR became positive before increased plasma CA125 in five out of six cases. Increased allele frequency of circulating tumor DNA (ctDNA) is associated with increased tumor volume after recurrence. ddPCR detected ctDNA signals significantly earlier than increased CA125 in the detection of OC recurrence by imaging (49 days and 7 days before, respectively: p < 0.05). No ctDNA was detected in the plasma of recurrence-free cases. Conclusions: Our results demonstrate the potential of identifying ctDNA by ddPCR as an early detection tool for OC recurrence.

  38. Establishment of a Diagnostic Method for Pelvic Sentinel Lymph Node Metastasis by Contrast-Enhanced Ultrasound in Uterine Cancer. International-journal Peer-reviewed

    Asami Toki, Hitoshi Niikura, Naoko Mori, Shogo Shigeta, Tomoyuki Nagai, Hideki Tokunaga, Muneaki Shimada, Nobuo Yaegashi

    Ultrasound in medicine & biology　47　(8)　2107-2116　2021/08

    DOI： 10.1016/j.ultrasmedbio.2021.03.040 　

    More details Close

    This study investigated the usefulness of conventional ultrasound (US) and contrast-enhanced ultrasound (CEUS) in distinguishing metastasis of pelvic sentinel lymph nodes (SLNs) in patients with gynecological cancer. We examined 74 SLNs of patients with endometrial cancer (n = 26) and cervical cancer (n = 11). Patients underwent US and CEUS followed by SLN biopsy; US and CEUS results were evaluated visually and quantitatively and compared between pathological metastasis-negative and -positive groups. To support CEUS results, the microvessel density of SLNs was evaluated immunohistochemically. Seventeen positive and 40 negative SLNs were evaluable. Margin and enhancement patterns by visual assessment revealed significant differences (p = 0.046 and 0.022, respectively). In quantitative time-intensity curve analyses, the weakest peak intensities (PImin), PI ratio and PI difference indicated significant differences (p = 0.045, p < 0.001 and p < 0.001, respectively). The areas under the receiver operating characteristic curves (AUCs) were 0.64, 0.82 and 0.83, respectively. The most effective PI ratio from the AUC was 1.3 (sensitivity = 82%, specificity = 70%), and the PI difference from the AUC was 20 (sensitivity = 88%, specificity = 70%). Microvessel density was significantly lower in metastatic lesions than in other areas. The quantitative analysis of CEUS seemed to be a reasonable method for distinguishing lymph node metastasis in patients with gynecological cancer.

  39. Wide-Targeted Metabolome Analysis Identifies Potential Biomarkers for Prognosis Prediction of Epithelial Ovarian Cancer. International-journal Peer-reviewed

    Eiji Hishinuma, Muneaki Shimada, Naomi Matsukawa, Daisuke Saigusa, Bin Li, Kei Kudo, Keita Tsuji, Shogo Shigeta, Hideki Tokunaga, Kazuki Kumada, Keigo Komine, Hidekazu Shirota, Yuichi Aoki, Ikuko N Motoike, Jun Yasuda, Kengo Kinoshita, Masayuki Yamamoto, Seizo Koshiba, Nobuo Yaegashi

    Toxins　13　(7)　2021/06/30

    DOI： 10.3390/toxins13070461 　

    More details Close

    Epithelial ovarian cancer (EOC) is a fatal gynecologic cancer, and its poor prognosis is mainly due to delayed diagnosis. Therefore, biomarker identification and prognosis prediction are crucial in EOC. Altered cell metabolism is a characteristic feature of cancers, and metabolomics reflects an individual's current phenotype. In particular, plasma metabolome analyses can be useful for biomarker identification. In this study, we analyzed 624 metabolites, including uremic toxins (UTx) in plasma derived from 80 patients with EOC using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Compared with the healthy control, we detected 77 significantly increased metabolites and 114 significantly decreased metabolites in EOC patients. Especially, decreased concentrations of lysophosphatidylcholines and phosphatidylcholines and increased concentrations of triglycerides were observed, indicating a metabolic profile characteristic of EOC patients. After calculating the parameters of each metabolic index, we found that higher ratios of kynurenine to tryptophan correlates with worse prognosis in EOC patients. Kynurenine, one of the UTx, can affect the prognosis of EOC. Our results demonstrated that plasma metabolome analysis is useful not only for the diagnosis of EOC, but also for predicting prognosis with the variation of UTx and evaluating response to chemotherapy.

  40. The trend and outcome of postsurgical therapy for high-risk early-stage cervical cancer with lymph node metastasis in Japan: a report from the Japan Society of Gynecologic Oncology (JSGO) guidelines evaluation committee. International-journal Peer-reviewed

    Masae Ikeda, Masako Shida, Shogo Shigeta, Satoru Nagase, Fumiaki Takahashi, Wataru Yamagami, Hidetaka Katabuchi, Nobuo Yaegashi, Daisuke Aoki, Mikio Mikami

    Journal of gynecologic oncology　32　(3)　e44　2021/05

    DOI： 10.3802/jgo.2021.32.e44 　

    More details Close

    OBJECTIVE: The Japan Society of Gynecologic Oncology published the first guidelines for the treatment of cervical cancer in 2007. The aim of this research was to evaluate the influence of the introduction of the first guideline on clinical trends and outcomes of patients with early-stage cervical cancer who underwent surgery. METHODS: This analysis included 9,756 patients who were diagnosed based on the pathological Tumor-Node-Metastasis (pTNM) classification (i.e., pT1b1, pT1b2, pT2b and pN0, pN1, pNX) and received surgery as a primary treatment between 2004 and 2009. Data of these patients were retrospectively reviewed, and clinicopathological trends were assessed. The influence of the introduction of the guideline on survival was determined by using a competing risk model. RESULTS: For surgery cases, the estimated subdistribution hazard ratio (HR) by the competing risk model for the influence of the guideline adjusted for age, year of registration, pT classification, pN classification, histological type, and treatment methods was 1.024 (p=0.864). Following the introduction of the first guideline in 2007, for patients with lymph node metastasis, the use of chemotherapy (CT) as a postsurgical therapy increased, whereas that of concurrent chemoradiotherapy (CCRT)/radiotherapy (RT) decreased (p<0.010). For pN1 cases, the estimated subdistribution HR by the competing risk model for the influence of the guideline was 1.094 (p=0.634). There was no significance in the postsurgical therapy between CT and CCRT/RT (p=0.078). CONCLUSIONS: Survival of surgical cases was not improved by the introduction of the guidelines. It is necessary to consider more effective postsurgical therapy for high-risk early-stage cervical cancer.

  41. Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. International-journal Peer-reviewed

    Shogo Shigeta, Goldie Y L Lui, Reid Shaw, Russell Moser, Kay E Gurley, Grace Durenberger, Rachele Rosati, Robert L Diaz, Tan A Ince, Elizabeth M Swisher, Carla Grandori, Christopher J Kemp

    Molecular cancer therapeutics　20　(4)　691-703　2021/04

    DOI： 10.1158/1535-7163.MCT-20-0809 　

    More details Close

    Ovarian clear cell carcinoma (OCCC) is a rare, chemo-resistant subtype of ovarian cancer. To identify novel therapeutic targets and combination therapies for OCCC, we subjected a set of patient-derived ovarian cancer cell lines to arrayed high-throughput siRNA and drug screening. The results indicated OCCC cells are vulnerable to knockdown of epigenetic gene targets such as bromodomain and extra-terminal domain (BET) proteins BRD2 and BRD3. Subsequent RNA interference assays, as well as BET inhibitor treatments, validated these BET proteins as potential therapeutic targets. Because development of resistance to single targeted agents is common, we next performed sensitizer drug screens to identify potential combination therapies with the BET inhibitor CPI0610. Several PI3K or AKT inhibitors were among the top drug combinations identified and subsequent work showed CPI0610 synergized with alpelisib or MK2206 by inducing p53-independent apoptosis. We further verified synergy between CPI0610 and PI3K-AKT pathway inhibitors alpelisib, MK2206, or ipatasertib in tumor organoids obtained directly from patients with OCCC. These findings indicate further preclinical evaluation of BET inhibitors, alone or in combination with PI3K-AKT inhibitors for OCCC, is warranted.

  42. Prospective evaluation of sentinel node navigation surgery in Japanese patients with low-risk endometrial cancer-safety and occurrence of lymphedema. International-journal Peer-reviewed

    Hitoshi Niikura, Asami Toki, Tomoyuki Nagai, Satoshi Okamoto, Shogo Shigeta, Hideki Tokunaga, Muneaki Shimada, Mika Watanabe, Nobuo Yaegashi

    Japanese journal of clinical oncology　51　(4)　584-589　2021/04/01

    DOI： 10.1093/jjco/hyaa252 　

    More details Close

    OBJECTIVE: The present study aimed to clarify the occurrence rate of lymphedema and prognosis in patients with endometrial cancer according to sentinel lymph node biopsy alone with intraoperative histopathological examination. METHODS: The study included 45 consecutive patients with endometrial cancer treated at Tohoku University Hospital between October 2014 and August 2017. All patients had endometrial carcinoma with endometrioid histology Grade 1 or Grade 2 confirmed by biopsy and stage I on magnetic resonance imaging and/or computed tomography at their preoperative evaluation. Sentinel lymph node detection was performed by radioisotope and dye. Patients who were diagnosed intraoperatively as negative for sentinel lymph node metastasis did not undergo further systematic pelvic lymphadenectomy. The occurrence rate of lymphedema and prognosis was evaluated. RESULTS: Bilateral sentinel lymph nodes were detected in 44 of 45 patients (97%). Forty-three patients underwent sentinel lymph node biopsy alone, and only two patients underwent systematic lymphadenectomy. Sentinel lymph node metastases were detected in one patient intraoperatively and two patients postoperatively as ITCs. No patients experienced recurrence. New symptomatic lower-extremity lymphedema was identified in one of 43 patients (2.3%) who underwent sentinel lymph node biopsy alone. CONCLUSION: Sentinel lymph node biopsy alone with intraoperative histopathological diagnosis appears to be a safe and effective strategy to detect lymph node metastasis and to reduce the number of patients with lower-extremity lymphedema among patients with endometrial cancer.

  43. A modified technique of laparoscopic radical trachelectomy combined with extracorporeal cervical amputation through a mini-laparotomy

    Zen Watanabe, Hideki Tokunaga, Masumi Ishibashi, Shogo Shigeta, Keita Tsuji, Tomoyuki Nagai, Masahito Tachibana, Muneaki Shimada, Nobuo Yaegashi

    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY　42　(1)　183-188　2021/02

    DOI： 10.31083/j.ejgo.2021.01.2278 　

    ISSN： 0392-2936

  44. Ceramide synthase 2-C24:1 -ceramide axis limits the metastatic potential of ovarian cancer cells. International-journal Peer-reviewed

    Xuewei Zhang, Wataru Sakamoto, Daniel Canals, Masumi Ishibashi, Masaya Matsuda, Kentaro Nishida, Masafumi Toyoshima, Shogo Shigeta, Makoto Taniguchi, Can E Senkal, Toshiro Okazaki, Nobuo Yaegashi, Yusuf A Hannun, Takeshi Nabe, Kazuyuki Kitatani

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology　35　(2)　e21287　2021/02

    DOI： 10.1096/fj.202001504RR 　

    More details Close

    Regulation of sphingolipid metabolism plays a role in cellular homeostasis, and dysregulation of these pathways is involved in cancer progression. Previously, our reports identified ceramide as an anti-metastatic lipid. In the present study, we investigated the biochemical alterations in ceramide-centered metabolism of sphingolipids that were associated with metastatic potential. We established metastasis-prone sublines of SKOV3 ovarian cancer cells using an in vivo selection method. These cells showed decreases in ceramide levels and ceramide synthase (CerS) 2 expression. Moreover, CerS2 downregulation in ovarian cancer cells promoted metastasis in vivo and potentiated cell motility and invasiveness. Moreover, CerS2 knock-in suppressed the formation of lamellipodia required for cell motility in this cell line. In order to define specific roles of ceramide species in cell motility controlled by CerS2, the effect of exogenous long- and very long-chain ceramide species on the formation of lamellipodia was evaluated. Treatment with distinct ceramides increased cellular ceramides and had inhibitory effects on the formation of lamellipodia. Interestingly, blocking the recycling pathway of ceramides by a CerS inhibitor was ineffective in the suppression of exogenous C24:1 -ceramide for the formation of lamellipodia. These results suggested that C24:1 -ceramide, a CerS2 metabolite, predominantly suppresses the formation of lamellipodia without the requirement for deacylation/reacylation. Moreover, knockdown of neutral ceramidase suppressed the formation of lamellipodia concomitant with upregulation of C24:1 -ceramide. Collectively, the CerS2-C24:1 -ceramide axis, which may be countered by neutral ceramidase, is suggested to limit cell motility and metastatic potential. These findings may provide insights that lead to further development of ceramide-based therapy and biomarkers for metastatic ovarian cancer.

  45. The Impact of Histological Subtype on Survival Outcome of Patients with Stage IIB-IVA Cervical Cancer Who Received Definitive Radiotherapy. Peer-reviewed

    Shuko Miyahara, Keita Tsuji, Muneaki Shimada, Yusuke Shibuya, Shogo Shigeta, Tomoyuki Nagai, Rei Umezawa, Hideki Tokunaga, Keiichi Jingu, Nobuo Yaegashi

    The Tohoku journal of experimental medicine　255　(4)　303-313　2021

    DOI： 10.1620/tjem.255.303 　

    More details Close

    The impact of histologic subtype on definitive radiotherapy for patients with locally advanced cervical cancer remains unclear. The aim of this retrospective analysis was to assess clinicopathological findings and clinical outcome by histological type in patients with stage IIB-IVA cervical cancer. Ninety-two patients with stage IIB-IVA [International Federation of Gynecology and Obstetrics (FIGO) 2008] cervical cancer, who underwent definitive radiotherapy between 2013 to 2018, were identified as eligible for this study. The clinical information of the eligible patients was obtained from medical records of our hospital. Seventy-eight patients underwent concurrent chemoradiotherapy, and the remaining 14 patients received radiotherapy alone. Of 92 patients, 83 had squamous cell carcinoma (SCC) and 9 had non-SCC histology. Progression-free survival (PFS) rate of patients with non-SCC was significantly worse than of those with SCC (2-year PFS: 62.0% vs. 12.5%, p = 0.0020), but overall survival (OS) rate did not statistically differ between the two subtypes (2-year OS: 82.4% vs. 62.5%, p = 0.2157). Pelvic failure-free (PFF) rate of patients with non-SCC histology was significantly worse than of those with non-SCC (2-year PFF; 88.2% vs. 25.0%, p < 0.0001). In univariate analysis, non-SCC histology was associated with PFS rate, although there was no association with OS rate. In multivariate analysis, non-SCC histology and lymph node metastasis were independent prognostic factors for shorter PFS. In patients with stage IIB-IVA cervical cancer who underwent definitive radiotherapy, patients with non-SCC showed significantly worse PFS rate than those with SCC.

  46. CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents. International-journal Peer-reviewed

    Yoshiko Oyama, Shogo Shigeta, Hideki Tokunaga, Keita Tsuji, Masumi Ishibashi, Yusuke Shibuya, Muneaki Shimada, Jun Yasuda, Nobuo Yaegashi

    PloS one　16　(6)　e0251079　2021

    DOI： 10.1371/journal.pone.0251079 　

    More details Close

    Platinum sensitivity is an important prognostic factor in patients with ovarian cancer. Chromodomain-helicase-DNA-binding protein 4 (CHD4) is a core member of the nucleosome remodeling and deacetylase complex, which functions as a chromatin remodeler. Emerging evidence indicates that CHD4 could be a potential therapeutic target for cancer therapy. The purpose of this study was to clarify the role of CHD4 in ovarian cancer and investigate its therapeutic potential focusing on platinum sensitivity. In an analysis of the Cancer Genome Atlas ovarian cancer dataset, CHD4 gene amplification was associated with worse overall survival. CHD4 mRNA expression was significantly higher in platinum-resistant samples in a subsequent clinical sample analysis, suggesting that CHD4 overexpression conferred platinum resistance to ovarian cancer cells, resulting in poor patient survival. In concordance with these findings, CHD4 knockdown enhanced the induction of apoptosis mediated by cisplatin in ovarian cancer cells TOV21G and increased cisplatin sensitivity in multiple ovarian cancer cells derived from different subtypes. However, CHD4 knockdown did not affect the expression of RAD51 or p21, the known targets of CHD4 in other cancer types that can modulate platinum sensitivity. Knockdown and overexpression assays revealed that CHD4 positively regulated the expression of multi-drug transporter MDR1 and its coding protein p-glycoprotein. In addition, a first-in-class CHD4/SMARCA5 inhibitor ED2-AD101 showed synergistic interactions with cisplatin. Our findings suggest that CHD4 mediates platinum sensitivity by modulating MDR1 expression in ovarian cancer. Further, CHD4 suppression has a potential to be a novel therapeutic strategy in combination with platinum agents.

  47. A Single Arm Prospective Pilot Study Examining the Efficacy and Safety of Bevacizumab Single Maintenance Therapy Following Platinum-Based Chemotherapy in Patients with Advanced or Recurrent Cervical Cancer. Peer-reviewed

    Masafumi Toyoshima, Muneaki Shimada, Satomi Sasaki, Masumi Ishibashi, Shogo Shigeta, Keita Tsuji, Tomoyuki Nagai, Hideki Tokunaga, Hitoshi Niikura, Nobuo Yaegashi

    The Tohoku journal of experimental medicine　254　(3)　145-153　2021

    DOI： 10.1620/tjem.254.145 　

    More details Close

    Although the addition of bevacizumab to platinum-based combination chemotherapy has been recommended as a standard regimen for patients with advanced or recurrent cervical cancer, there is no clear evidence regarding the effectiveness of bevacizumab monotherapy as salvage chemotherapy. This study prospectively examined the efficacy and safety of switching from platinum-based chemotherapy combined with bevacizumab to single maintenance therapy in patients with advanced or recurrent cervical cancer. Patients were first treated with standard combination chemotherapy. However, if chemotherapy was discontinued because of an adverse event, bevacizumab monotherapy was continued for patients who agreed to participate in this study and provided written informed consent. The study protocol was approved by the Independent Review Board of Tohoku University School of Medicine (reception number 2017-1-540). A total of 15 patients (median age of 55 years, range 33-69 years) participated in this study. The median number of cycles of bevacizumab single maintenance administration was 8, and the main reasons for discontinuation were disease progression and adverse events. Bevacizumab single maintenance therapy had a disease control rate of 53.3% (CR 40%, PR 6.7%, SD 6.7%). The most frequent grade 3/4 clinical adverse events were proteinuria (5/15) and hypertension (4/15). No treatment-related deaths occurred. Bevacizumab single maintenance therapy was effective as salvage chemotherapy in patients with advanced or recurrent cervical cancer, and the safety profile was generally consistent with those reported in previous studies of bevacizumab monotherapy.

  48. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2). International-journal Peer-reviewed

    Hideki Tokunaga, Keita Iida, Atsushi Hozawa, Soichi Ogishima, Yoh Watanabe, Shogo Shigeta, Muneaki Shimada, Yumi Yamaguchi-Kabata, Shu Tadaka, Fumiki Katsuoka, Shin Ito, Kazuki Kumada, Yohei Hamanaka, Nobuo Fuse, Kengo Kinoshita, Masayuki Yamamoto, Nobuo Yaegashi, Jun Yasuda

    PloS one　16　(1)　e0236907　2021

    DOI： 10.1371/journal.pone.0236907 　

    More details Close

    Identification of the population frequencies of definitely pathogenic germline variants in two major hereditary breast and ovarian cancer syndrome (HBOC) genes, BRCA1/2, is essential to estimate the number of HBOC patients. In addition, the identification of moderately penetrant HBOC gene variants that contribute to increasing the risk of breast and ovarian cancers in a population is critical to establish personalized health care. A prospective cohort subjected to genome analysis can provide both sets of information. Computational scoring and prospective cohort studies may help to identify such likely pathogenic variants in the general population. We annotated the variants in the BRCA1 and BRCA2 genes from a dataset of 3,552 whole-genome sequences obtained from members of a prospective cohorts with genome data in the Tohoku Medical Megabank Project (TMM) with InterVar software. Computational impact scores (CADD_phred and Eigen_raw) and minor allele frequencies (MAFs) of pathogenic (P) and likely pathogenic (LP) variants in ClinVar were used for filtration criteria. Familial predispositions to cancers among the 35,000 TMM genome cohort participants were analyzed to verify the identified pathogenicity. Seven potentially pathogenic variants were newly identified. The sisters of carriers of these moderately deleterious variants and definite P and LP variants among members of the TMM prospective cohort showed a statistically significant preponderance for cancer onset, from the self-reported cancer history. Filtering by computational scoring and MAF is useful to identify potentially pathogenic variants in BRCA genes in the Japanese population. These results should help to follow up the carriers of variants of uncertain significance in the HBOC genes in the longitudinal prospective cohort study.

  49. Involvement of small extracellular vesicle-derived TIE-1 in the chemoresistance of ovarian cancer cells. International-journal Peer-reviewed

    Tomoka Misawa, Masafumi Toyoshima, Kazuyuki Kitatani, Masumi Ishibashi, Junko Hasegawa-Minato, Shogo Shigeta, Nobuo Yaegashi

    Cancer treatment and research communications　27　100364-100364　2021

    DOI： 10.1016/j.ctarc.2021.100364 　

    More details Close

    BACKGROUND: Ovarian cancer is the most lethal gynecologic malignancy due to the tumor's acquisition of chemoresistance to platinum-based chemotherapy. To solve this problem, we conducted RNAi-based large-scale screening and determined that tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (TIE-1) is a key molecule involved in the platinum resistance of ovarian cancer cells. Recently, a variety of studies have investigated that small extracellular vesicles (sEVs) contribute to the communication between cancer cells, including the development of chemoresistance in ovarian cancer. The purpose of our study is to determine if sEVs-derived TIE-1 is involved in the chemoresistance of ovarian cancer cells. MATERIALS AND METHODS: TIE-1-overexpressed TOV112D cells, termed TOV112DTIE-1 cells, were established, and sEVs were isolated from TOV112DTIE-1 cells supernatants by ultracentrifugation. We assessed cisplatin sensitivity in recipient cells with TOV112DTIE-1-derived sEVs by cell-Titer Glo kit. We also asked whether sEV-derived TIE-1 suppressed the DNA damage response in recipient cells and evaluated the DNA damage response by counting cells positive for DNA damage foci. RESULTS: TIE-1 was contained within sEVTIE-1 derived from the cellular supernatant of TOV112DTIE-1. We showed that sEV-derived TIE-1 decreased chemosensitivity to cisplatin by suppressing the DNA damage response in recipient cells. CONCLUSION: Our findings suggest that sEV-derived TIE-1 could be a new therapeutic target for refractory ovarian cancer.

  50. Epidemiological guideline influence on the therapeutic trend and patient outcome of uterine cervical cancer in Japan: Japan society of gynecologic oncology guideline evaluation committee project. International-journal Peer-reviewed

    Shogo Shigeta, Masako Shida, Satoru Nagase, Masae Ikeda, Fumiaki Takahashi, Takeo Shibata, Wataru Yamagami, Hidetaka Katabuchi, Nobuo Yaegashi, Daisuke Aoki, Mikio Mikami

    Gynecologic oncology　159　(1)　248-255　2020/10

    DOI： 10.1016/j.ygyno.2020.07.023 　

    More details Close

    OBJECTIVE: The Japan Society of Gynecologic Oncology published its first clinical guidelines for uterine cervical cancer in 2007 which has been revised twice in 2011 and 2017. The aim of this study was to investigate the influence of the first guideline publication on the therapeutic trend and patient outcome by analyzing uterine cervical cancer cases registered to the cancer registry organized by the Japan Society of Obstetrics and Gynecology. METHODS: Data of uterine cervical cancer cases registered to the cancer registry from 2000 to 2012 were provided. Epidemiological and clinical trend were analyzed by the Chi-squared test with subsequent standardized residual analysis. Overall survival among the patients registered between 2004 and 2009 was analyzed using the Fine and Gray competing risk model. RESULTS: 68,707 cases were registered during the study period. A trend analysis revealed that the guideline publication may have led to a decrease in neoadjuvant chemotherapy in parallel with an increase in radiation therapy mainly in stage II and III patients undergoing primary treatment. A survival analysis indicated that the introduction of the guideline may have improved overall survival among stage III uterine cervical cancer patients, even though a significant difference was not observed in all of the cases. CONCLUSIONS: This study demonstrated the potential influence of the guideline publication on the clinical trend and patient outcome. As this is the first assessment of the guideline for uterine cervical cancer in Japan, continuous evaluation is necessary to further comprehend the significance of this guideline.

  51. MicroRNA Let-7c Contributes to Paclitaxel Resistance via Aurora-B in Endometrial Serous Carcinoma. Peer-reviewed

    Izumi Sato, Masumi Ishibashi, Hideki Tokunaga, Shogo Shigeta, Shoko Sakurada, Muneaki Shimada, Satoru Nagase, Yoh Watanabe, Nobuo Yaegashi

    The Tohoku journal of experimental medicine　251　(4)　263-272　2020/08

    DOI： 10.1620/tjem.251.263 　

    More details Close

    The incidence of endometrial cancer has rapidly risen over recent years. Paclitaxel, a key drug for endometrial cancer treatment, inhibits microtubule depolymerization and induces apoptosis in cancer cells. Endometrial serous carcinoma (ESC) accounts for < 10% of all endometrial carcinomas, but its aggressive nature makes it responsible for close to 40% of cancer deaths. Thus, novel therapeutic targets are required for ESC. To identify microRNAs that promote paclitaxel resistance, we established two paclitaxel-resistant cell lines from USPC1 human ESC cells by exposing paclitaxel to parental cells for 12 weeks. Paclitaxel concentrations were increased every 2 weeks, and after 12 weeks of paclitaxel exposure, two replicate paclitaxel-resistant cell lines were established (USPC1-PTSR1 and USPC1-PTXR2). The microarray analysis was performed using USPC1 cells and USPC1-PTXR1 cells, and eight candidate microRNAs were thus selected as potential mediators of paclitaxel sensitivity. Among these candidate microRNAs, let-7c precursor treatment of paclitaxel-resistant USPC1-PTXR1 cells caused the greatest increase in paclitaxel-mediated cytotoxicity. Let-7c inhibition conversely decreased paclitaxel-induced apoptosis. It is known that let-7a microRNA, a member of the let-7 family, inhibits growth of endometrial carcinoma cells targeting Aurora-B that controls progression through each phase of mitosis. We thus studied whether let-7c mediates Aurora-B expression in ESC cells. The expression levels of Aurora-B mRNA and protein were higher in USPC-PTXR1 cells compared with USPC1 cells. Let-7c inhibition increased Aurora-B expression in USPC1 cells but decreased Aurora-B expression in USPC1-PTXR1 cells. These results indicate that let-7c mediates paclitaxel resistance via inhibition of Aurora-B expression in ESC cells.

  52. Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan. International-journal Peer-reviewed

    Mamiko Onuki, Koji Matsumoto, Takashi Iwata, Kasumi Yamamoto, Yoichi Aoki, Shoji Maenohara, Naotake Tsuda, Shoji Kamiura, Kazuhiro Takehara, Koji Horie, Nobutaka Tasaka, Hideaki Yahata, Yuji Takei, Yoichi Aoki, Hisamori Kato, Takeshi Motohara, Keiichiro Nakamura, Mitsuya Ishikawa, Tatsuya Kato, Hiroyuki Yoshida, Noriomi Matsumura, Hidekatsu Nakai, Shogo Shigeta, Fumiaki Takahashi, Kiichiro Noda, Nobuo Yaegashi, Hiroyuki Yoshikawa

    Cancer science　111　(7)　2546-2557　2020/07

    DOI： 10.1111/cas.14445 　

    More details Close

    To obtain baseline data for cervical cancer prevention in Japan, we analyzed human papillomavirus (HPV) data from 5045 Japanese women aged less than 40 years and diagnosed with cervical abnormalities at 21 hospitals during 2012-2017. These included cervical intraepithelial neoplasia grade 1 (CIN1, n = 573), CIN2-3 (n = 3219), adenocarcinoma in situ (AIS, n = 123), and invasive cervical cancer (ICC, n = 1130). The Roche Linear Array was used for HPV genotyping. The HPV type-specific relative contributions (RCs) were estimated by adding multiple infections to single types in accordance with proportional weighting attributions. Based on the comparison of type-specific RCs between CIN1 and CIN2-3/AIS/ICC (CIN2+), RC ratios were calculated to estimate type-specific risks for progression to CIN2+. Human papillomavirus DNA was detected in 85.5% of CIN1, 95.7% of CIN2-3/AIS, and 91.2% of ICC. Multiple infections decreased with disease severity: 42.9% in CIN1, 40.4% in CIN2-3/AIS, and 23.7% in ICC (P < .0001). The relative risk for progression to CIN2+ was highest for HPV16 (RC ratio 3.78, 95% confidence interval [CI] 3.01-4.98), followed by HPV31 (2.51, 1.54-5.24), HPV18 (2.43, 1.59-4.32), HPV35 (1.56, 0.43-8.36), HPV33 (1.01, 0.49-3.31), HPV52 (0.99, 0.76-1.33), and HPV58 (0.97, 0.75-1.32). The relative risk of disease progression was 1.87 (95% CI, 1.71-2.05) for HPV16/18/31/33/35/45/52/58, but only 0.17 (95% CI, 0.14-0.22) for HPV39/51/56/59/66/68. Human papillomavirus 16/18/31/33/45/52/58/6/11 included in a 9-valent vaccine contributed to 89.7% (95% CI, 88.7-90.7) of CIN2-3/AIS and 93.8% (95% CI, 92.4-95.3) of ICC. In conclusion, our data support the Japanese guidelines that recommend discriminating HPV16/18/31/33/35/45/52/58 genotypes for CIN management. The 9-valent vaccine is estimated to provide over 90% protection against ICC in young Japanese women.

  53. Potential of Tyrosine Kinase Receptor TIE-1 as Novel Therapeutic Target in High-PI3K-Expressing Ovarian Cancer. International-journal Peer-reviewed

    Xuewei Zhang, Masumi Ishibashi, Kazuyuki Kitatani, Shogo Shigeta, Hideki Tokunaga, Masafumi Toyoshima, Muneaki Shimada, Nobuo Yaegashi

    Cancers　12　(6)　2020/06/26

    DOI： 10.3390/cancers12061705 　

    More details Close

    Tyrosine kinase receptor TIE-1 plays a critical role in angiogenesis and blood-vessel stability. In recent years, increased TIE-1 expression has been observed in many types of cancers; however, the biological significance and underlying mechanisms remain unknown. Thus, in the present study, we investigated the tumor biological functions of TIE-1 in ovarian cancer. The treatment of SKOV3 ovarian-cancer cells with siRNA against TIE-1 decreased the expression of key molecules in the PI3K/Akt signaling pathway, such as p110α and phospho-Akt, suggesting that TIE-1 is related to the PI3K/Akt pathway. Furthermore, the knockdown of TIE-1 significantly decreased cell proliferation in high-PI3K-expressing cell lines (SKOV3, CAOV3) but not low-PI3K-expressing cell lines (TOV112D, A2780). These results suggested that inhibition of TIE-1 decreases cell growth in high-PI3K-expressing cells. Moreover, in low-PI3K-expressing TOV112D ovarian-cancer cells, TIE-1 overexpression induced PI3K upregulation and promoted a PI3K-mediated cell proliferative phenotype. Mechanistically, TIE-1 participates in cell growth and proliferation by regulating the PI3K/Akt signaling pathway. Taken together, our findings strongly implicate TIE-1 as a novel therapeutic target in high-PI3K-expressing ovarian-cancer cells.

  54. Clinical and reproductive outcomes of fertility-sparing surgery in stage I epithelial ovarian cancer. International-journal Peer-reviewed

    Takafumi Watanabe, Shu Soeda, Hiroshi Nishiyama, Yuichiroh Kiko, Hideki Tokunaga, Shogo Shigeta, Nobuo Yaegashi, Hidekazu Yamada, Tsuyoshi Ohta, Satoru Nagase, Tadahiro Shoji, Masahiro Kagabu, Tsukasa Baba, Dai Shimizu, Naoki Sato, Yukihiro Terada, Masayuki Futagami, Yoshihito Yokoyama, Keiya Fujimori

    Molecular and clinical oncology　12　(1)　44-50　2020/01

    DOI： 10.3892/mco.2019.1954 　

    ISSN： 2049-9450

    More details Close

    The aim of the present study was to evaluate the oncologic safety and reproductive outcome in patients with stage I epithelial ovarian cancer (EOC) treated with fertility-sparing surgery (FSS). Women aged ≤40 years with stage I EOC who had undergone FSS between 2000 and 2010 were retrospectively reviewed. Survival was examined using the Kaplan-Meier method and statistical significance was analyzed using the log-rank test. A total of 29 EOC patients (stage IA, n=14; stage IC1 n=6; stage IC3, n=9) from seven participating institutions belonging to the Tohoku Gynecologic Cancer Unit were enrolled. After a median follow-up duration of 60.6 months (range, 6-135 months), five patients (17.2%) experienced tumor recurrence. The respective five-year relapse-free survival (RFS) and overall survival (OS) rates were 90.9 and 100% for stage IA/IC1, and 43.8 and 87.5% for stage IC3. Significant differences in RFS were observed between stage IA/IC1 and IC3 patients (P=0.026). However, there was no significant difference in OS between patients with 1A/1C1 and those with 1C3 (P=0.712). After FSS, seven pregnancies occurred in five patients, which resulted in the birth of six healthy children. The results of the present study confirmed that FSS may be an acceptable treatment method for stage IA and IC1 EOC, exhibiting a favorable reproductive outcome. However, the safety of FSS for treating stage IC3 EOC is uncertain and warrants further investigation.

  55. Reduction in HPV16/18 prevalence among young women with high-grade cervical lesions following the Japanese HPV vaccination program. Peer-reviewed

    Matsumoto K, Yaegashi N, Iwata T, Yamamoto K, Aoki Y, Okadome M, Ushijima K, Kamiura S, Takehara K, Horie K, Tasaka N, Sonoda K, Takei Y, Aoki Y, Konnai K, Katabuchi H, Nakamura K, Ishikawa M, Watari H, Yoshida H, Matsumura N, Nakai H, Shigeta S, Takahashi F, Noda K, Yoshikawa H, MINT Study Group

    Cancer science　110　(12)　3811-3820　2019/10

    Publisher: Wiley

    DOI： 10.1111/cas.14212 　

    ISSN： 1347-9032

    eISSN： 1349-7006

  56. La-Related Protein 4 as a Suppressor for Motility of Ovarian Cancer Cells. Peer-reviewed

    Egiz M, Usui T, Ishibashi M, Zhang X, Shigeta S, Toyoshima M, Kitatani K, Yaegashi N

    The Tohoku journal of experimental medicine　247　(1)　59-67　2019/01

    DOI： 10.1620/tjem.247.59 　

    ISSN： 0040-8727

    More details Close

    The La-related proteins (LARPs) are a family of RNA binding proteins that control the degradation and stabilization of RNAs. As emerging research reveals the biology of each LARP, it is evident that LARPs are dysregulated in some types of cancer. Upregulation of cell motility potentiates the metastatic potential of ovarian cancer cells; however, the roles of LARPs in cell motility remain unknown. In the present study, we investigated the roles of LARPs in the progression of ovarian cancer using SKOV3 human ovarian cancer cells and a public database that integrates microarray-based gene expression data and clinical data. To explore the involvement of LARPs in the cell motility, we performed RNA interference screening for LARP mRNAs in SKOV3 cells. The screening identified LARP4 as a potential suppressor of the formation of lamellipodia. Conversely, enforced expression of LARP4 suppressed the formation of lamellipodia. Moreover, cell migration was significantly increased in LARP4-depleted SKOV3 cells. Mechanistically, LARP4 depletion was associated with the decrease in RhoA protein expression. These results suggest that LARP4 may limit RhoA-dependent cell motility. In a mouse xenograft model with SKOV3 cells, LARP4 depletion potentiated peritoneal metastasis. Upon analysis of a public database of patients with ovarian cancer, the LARP4 mRNA-high expression group (n = 166) showed longer overall survival compared with the LARP4 mRNA-low expression group (n = 489), implying a positive correlation of LARP4 mRNA levels in ovarian cancer tissues with patient prognosis. Taken together, we propose that LARP4 could suppress motility and metastatic potential of ovarian cancer cells.

  57. Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer. International-journal Peer-reviewed

    Ishibashi M, Toyoshima M, Zhang X, Hasegawa-Minato J, Shigeta S, Usui T, Kemp CJ, Grandori C, Kitatani K, Yaegashi N

    Scientific reports　8　(1)　13207-13207　2018/09

    DOI： 10.1038/s41598-018-31069-2 　

    More details Close

    Platinum resistance is one of the most challenging problems in ovarian cancer treatment. High-throughput functional siRNA screening identified tyrosine kinase with immunoglobulin-like and EGF-like domains 1 (TIE-1) as a gene that confers cells resistant to cisplatin. Conversely enforced over-expression of TIE-1 was validated to decrease cisplatin sensitivity in multiple ovarian cancer cell lines and up-regulation of TIE-1 was correlated with poor prognosis and cisplatin resistance in patients with ovarian cancer. Mechanistically, TIE-1 up-regulates the nucleotide excision repair (NER) system mediated by xeroderma pigmentosum complementation group C (XPC), thereby leading to decreased susceptibility to cisplatin-induced cell death without affecting cisplatin uptake and excretion. Importantly potentiation of therapeutic efficacy by TIE-1 inhibition was selective to DNA-adduct-type chemotherapeutic platinum reagents. Therefore, TIE-1 is suggested to promote XPC-dependent NER, rendering ovarian cancer cells resistant to platinum. Accompanied with novel findings, TIE-1 could represent as a novel therapeutic target for platinum-resistant ovarian cancer.

  58. Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel. International-journal Peer-reviewed

    Seino M, Ohta T, Sugiyama A, Sakaki H, Sudo T, Tsutsumi S, Shigeta S, Tokunaga H, Toyoshima M, Yaegashi N, Nagase S

    Oncotarget　9　(62)　31985-31998　2018/08

    DOI： 10.18632/oncotarget.25868 　

    More details Close

    Introduction: Uterine serous carcinoma (USC) is more aggressive than other subtypes of endometrial carcinoma and is associated with a poor prognosis. We analyzed the metabolomic profile of USC with acquired resistance to paclitaxel. Results: Glutathione (GSH) concentration in PTX-1 cells was higher than in USPC-1 cells. In addition, GSH concentration in the USPC-1 cells increased after treatment with paclitaxel but was unchanged in PTX-1 cells. Glucose-6-phosphate (G6P) and ribose-5-phosphate (R5P) concentrations in PTX-1 cells were higher than those in USPC-1 cells. G6P concentration in the USPC-1 cells was unchanged after treatment with paclitaxel, while it decreased in PTX-1 cells. Conclusion: Our results indicate that increased GSH and glucose metabolism may be related to acquiring resistance to paclitaxel in USC and thus may be targets for anti-USC therapy. Materials and Methods: We compared metabolic profiles and reactions to paclitaxel in both a wild type USC cell line (USPC-1) and PTX-1, a cell line derived from USPC-1 which acquired paclitaxel resistance, using a capillary electrophoresis CE-MS/MS system.

  59. Ceramide nanoliposomes as a MLKL-dependent, necroptosis-inducing, chemotherapeutic reagent in ovarian cancer Peer-reviewed

    Xuewei Zhang, Kazuyuki Kitatani, Masafumi Toyoshima, Masumi Ishibashi, Toshinori Usui, Junko Minato, Mahy Egiz, Shogo Shigeta, Todd Fox, Tye Deering, Mark Kester, Nobuo Yaegashi

    Molecular Cancer Therapeutics　17　(1)　50-59　2018/01/01

    Publisher: American Association for Cancer Research Inc.

    DOI： 10.1158/1535-7163.MCT-17-0173 　

    ISSN： 1538-8514 1535-7163

    eISSN： 1538-8514

  60. Novel cooperative pathway of c-Myc and Furin, a pro-protein convertase, in cell proliferation as a therapeutic target in ovarian cancers Peer-reviewed

    Junko Hasegawa-Minato, Masafumi Toyoshima, Masumi Ishibashi, Xuewei Zhang, Shogo Shigeta, Carla Grandori, Kazuyuki Kitatani, Nobuo Yaegashi

    Oncotarget　9　(3)　3483-3496　2018

    Publisher: Impact Journals LLC

    DOI： 10.18632/oncotarget.23322 　

    ISSN： 1949-2553

    eISSN： 1949-2553

  61. Assessing the effect of guideline introduction on clinical practice and outcome in patients with endometrial cancer in Japan: a project of the Japan Society of Gynecologic Oncology (JSGO) guideline evaluation committee Peer-reviewed

    Shogo Shigeta, Satoru Nagase, Mikio Mikami, Masae Ikeda, Masako Shida, Isao Sakaguchi, Norichika Ushioda, Fumiaki Takahashi, Wataru Yamagami, Nobuo Yaegashi, Yasuhiro Udagawa, Hidetaka Katabuchi

    JOURNAL OF GYNECOLOGIC ONCOLOGY　28　(6)　e76　2017/11

    DOI： 10.3802/jgo.2017.28.e76 　

    ISSN： 2005-0380

    eISSN： 2005-0399

  62. Leptomeningeal metastasis from gynecologic cancers diagnosed by brain MRI Peer-reviewed

    Masafumi Toyoshima, Keita Tsuji, Shogo Shigeta, Hideki Tokunaga, Kiyoshi Ito, Yoh Watanabe, Kosuke Yoshinaga, Takeo Otsuki, Hitoshi Niikura, Nobuo Yaegashi

    CLINICAL IMAGING　41　42-47　2017/01

    DOI： 10.1016/j.clinimag.2016.09.013 　

    ISSN： 0899-7071

    eISSN： 1873-4499

  63. Eccrine porocarcinoma of the vulva: a case report and review of the literature Peer-reviewed

    Ayako Fujimine-Sato, Masafumi Toyoshima, Shogo Shigeta, Asami Toki, Takashi Kuno, Izumi Sato, Mika Watanabe, Hitoshi Niikura, Nobuo Yaegashi

    Journal of Medical Case Reports　10　(1)　1-5　2016/11/10

    Publisher: BioMed Central Ltd.

    DOI： 10.1186/s13256-016-1106-1 　

    ISSN： 1752-1947

    eISSN： 1752-1947

  64. Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer Peer-reviewed

    S. Shigeta, M. Toyoshima, K. Kitatani, M. Ishibashi, T. Usui, N. Yaegashi

    ONCOGENE　35　(27)　3577-3586　2016/07

    DOI： 10.1038/onc.2015.425 　

    ISSN： 0950-9232

    eISSN： 1476-5594

  65. Ceramide limits phosphatidylinositol-3-kinase C2 beta-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid Peer-reviewed

    K. Kitatani, T. Usui, S. K. Sriraman, M. Toyoshima, M. Ishibashi, S. Shigeta, S. Nagase, M. Sakamoto, H. Ogiso, T. Okazaki, Y. A. Hannun, V. P. Torchilin, N. Yaegashi

    ONCOGENE　35　(21)　2801-2812　2016/05

    DOI： 10.1038/onc.2015.330 　

    ISSN： 0950-9232

    eISSN： 1476-5594

  66. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer Peer-reviewed

    Satsuki Mashiko, Kazuyuki Kitatani, Masafumi Toyoshima, Atsuhiko Ichimura, Takashi Dan, Toshinori Usui, Masumi Ishibashi, Shogo Shigeta, Satoru Nagase, Toshio Miyata, Nobuo Yaegashi

    CANCER BIOLOGY & THERAPY　16　(2)　253-260　2015/02

    DOI： 10.1080/15384047.2014.1001271 　

    ISSN： 1538-4047

    eISSN： 1555-8576

  67. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan Peer-reviewed

    Tadao Takano, Hitoshi Niikura, Kiyoshi Ito, Satoru Nagase, Hiroki Utsunomiya, Takeo Otsuki, Masafumi Toyoshima, Hideki Tokunaga, Michiko Kaiho-Sakuma, Naomi Shiga, Tomoyuki Nagai, Sota Tanaka, Ai Otsuki, Hiroki Kurosawa, Shogo Shigeta, Keita Tsuji, Takuhiro Yamaguchi, Nobuo Yaegashi

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY　19　(5)　897-905　2014/10

    DOI： 10.1007/s10147-013-0627-5 　

    ISSN： 1341-9625

    eISSN： 1437-7772

  68. [Diagnosis and treatment of uterine leiomyosarcoma].

    Shigeta S, Nagase S, Yaegashi N

    Nihon rinsho. Japanese journal of clinical medicine　70 Suppl 4　452-455　2012/06

    ISSN： 0047-1852

  69. Impact of the Tohoku Region Pacific Coast Earthquake and Tsunami Disaster on Perinatal Outcome Peer-reviewed

    Sugawara Junichi, Chisaka Hiroshi, Hoshiai Tetsuro, Sato Kazuyo, Ugajin Tomohisa, Shigeta Shogo, Hasegawa Yoshimi, Okamura Kunihiro, Yaegashi Nobuo

    REPRODUCTIVE SCIENCES　19　(S3)　135A　2012/03

    ISSN： 1933-7191

Show all ︎Show first 5

Misc. 168

  1. 診療データベースを用いたカルテスクリーニング

    柴田大作, 辻川剛範, 渋谷恵, 森田智子, 久保雅洋, 中川敦寛, 重田昌吾, 島田宗昭

    言語処理学会年次大会発表論文集(Web)　31st　2025

    ISSN： 2188-4420

  2. An Integration of Multifaceted Research Platforms for the Development of Novel Therapeutic Strategies for Ovarian Clear Cell Carcinoma

    重田昌吾

    日本産科婦人科学会雑誌　76　(9)　907-917　2024/09

    Publisher: (公社)日本産科婦人科学会

    ISSN： 0300-9165

  3. 婦人科がんMISのnext innovation 卵巣がん手術における低侵襲手術の有効性と安全性 Systematic Reviewとメタ分析

    町田 弘子, 横井 暁, 島田 宗昭, 重田 昌吾, 古川 茂宜, 西川 伸道, 野村 弘行, 堀 謙輔, 徳永 英樹, 庄子 忠宏, 馬場 長, 永瀬 智

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　133-133　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  4. 血漿メタボローム解析を用いた婦人科癌におけるバイオマーカーの探索

    菱沼 英史, 島田 宗昭, 松川 直美, 萩原 達也, 工藤 敬, 渋谷 祐介, 重田 昌吾, 元池 育子, 徳永 英樹, 木下 賢吾, 小柴 生造, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　252-252　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  5. 卵巣明細胞癌におけるゲノム情報と予後についての関連解析

    宮原 周子, 久木元 詩央香, 栃木 実佳子, 橋本 栄文, 萩原 達也, 清水 孝規, 遠藤 俊, 吉泉 絵理, 工藤 敬, 渋谷 祐介, 湊 純子, 岡村 容伸, 石橋 ますみ, 重田 昌吾, 徳永 英樹, 島田 宗昭

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　257-257　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  6. 子宮頸癌における血漿メタボローム解析を用いた治療効果予測バイオマーカーの探索

    萩原 達也, 島田 宗昭, 菱沼 英史, 李 賓, 久木元 詩央香, 栃木 実佳子, 清水 孝規, 宮原 周子, 吉泉 絵理, 湊 純子, 渋谷 祐介, 橋本 千明, 石橋 ますみ, 重田 昌吾, 徳永 英樹, 小柴 生造, 齋藤 昌利, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　260-260　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  7. 血漿メタボローム解析を用いた子宮頸癌代謝プロファイリングの再検証

    太田真理子, 太田真理子, 島田宗昭, 島田宗昭, 菱沼英史, 李賓, 久木元詩央香, 萩原達也, 栃木実佳子, 清水孝規, 宮原周子, 吉泉絵理, 湊純子, 渋谷祐介, 橋本千明, 石橋ますみ, 重田昌吾, 徳永英樹, 小柴生造, 八重樫伸生, 八重樫伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集(Web)　66th　261-261　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  8. プラチナ感受性再発卵巣癌に対するPARP阻害剤再投与に関する検討

    吉泉 絵理, 重田 昌吾, 久木元 詩央香, 栃木 実佳子, 橋本 栄文, 萩原 達也, 遠藤 俊, 清水 孝規, 宮原 周子, 渋谷 祐介, 湊 純子, 石橋 ますみ, 橋本 千明, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　271-271　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  9. 血中代謝産物に着目した経時的リキッドバイオプシーによる進行再発卵巣癌モニタリング法の開発

    重田 昌吾, 菱沼 英史, 島田 宗昭, 渋谷 祐介, 湊 敬道, 安田 純, 湊 純子, 橋本 千明, 石橋 ますみ, 小柴 生造, 徳永 英樹, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　272-272　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  10. 卵巣癌における口腔内メタゲノム解析によるバイオマーカーの探索

    橋本 千明, 島田 宗昭, 齋藤 さかえ, 玉原 亨, 李 賓, 菱沼 英史, 青木 裕一, 渋谷 祐介, 久木元 詩央香, 栃木 実佳子, 萩原 達也, 清水 孝規, 工藤 敬, 湊 純子, 石橋 ますみ, 重田 昌吾, 徳永 英樹, 清水 律子, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　275-275　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  11. 一般住民コホート参加者に対する遺伝性乳がん卵巣がんの遺伝情報回付事業

    湊 純子, 島田 宗昭, 栃木 実佳子, 大根田 絹子, 濱中 洋平, 宮原 周子, 渋谷 祐介, 橋本 千明, 石橋 ますみ, 重田 昌吾, 徳永 英樹

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　332-332　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  12. 組織型の確定診断に難渋した子宮癌肉腫

    石橋 ますみ, 宮原 周子, 渋谷 祐介, 湊 純子, 橋本 千明, 重田 昌吾, 徳永 英樹, 室山 佑希, 藤島 史喜, 島田 宗昭, 森谷 卓也

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　352-352　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  13. 子宮肉腫との鑑別が問題となった子宮体部未分化癌の一例

    橋本 亮平, 谷口 智紀, 西本 光男, 國吉 真平, 重田 昌吾

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　66回　353-353　2024/07

    Publisher: (公社)日本婦人科腫瘍学会

  14. 外陰癌治療後の骨盤臓器脱に対する前後腟壁形成に合併した外陰膿瘍

    石橋ますみ, 徳永英樹, 清水孝規, 渋谷祐介, 重田昌吾, 島田宗昭, 島田宗昭

    産婦人科手術　(35)　154-154　2024/06

    Publisher: (株)メジカルビュー社

    ISSN： 0915-8375

  15. 【子宮頸がん撲滅へ向けた戦略-ワクチンと検診の新たなトレンドは?】HPVワクチン 2価・4価HPVワクチンの効果

    橋本 千明, 重田 昌吾, 島田 宗昭

    臨床婦人科産科　78　(6)　490-494　2024/06

    Publisher: (株)医学書院

    ISSN： 0386-9865

    eISSN： 1882-1294

  16. 革新的技術の統合がもたらす婦人科がん治療の未来 多角的研究基盤を統合した探索的研究に基づく卵巣明細胞癌の新規個別化医療開発

    重田 昌吾

    日本産科婦人科学会雑誌　76　(臨増)　S-23　2024/02

    Publisher: (公社)日本産科婦人科学会

    ISSN： 0300-9165

  17. 急速な進行を衷し子宮肉腫との鑑別に苦慮した子宮体部未分化癌の一例

    橋本 亮平, 西本 光男, 谷口 智紀, 重田 昌吾

    日本産科婦人科学会雑誌　76　(臨増)　S-554　2024/02

    Publisher: (公社)日本産科婦人科学会

    ISSN： 0300-9165

  18. リスク低減卵管卵巣摘出後の身体的・心理的影響

    湊純子, 島田宗昭, 原田成美, 柳垣美歌, 栃木実佳子, 石橋ますみ, 重田昌吾, 徳永英樹

    日本遺伝性腫瘍学会学術集会プログラム・抄録集　30th　2024

  19. SLNのデータに基づき,早期子宮体癌手術における骨盤リンパ節郭清を再考する

    永井智之, 橋本栄文, 海法道子, 藤田信弘, 重田昌吾, 徳永英樹, 島田宗昭, 新倉仁, 山田秀和

    日本婦人科ロボット手術学会プログラム・抄録集(Web)　12th　2024

  20. 再発卵巣癌に対するニラパリブの安全性と有効性を検討する観察研究;JGOG3031試験

    藤原聡枝, 島田宗昭, 野村弘行, 梶山広明, 鍵村達夫, 加藤愛, 田部宏, 竹井裕二, 黒田高史, 横須幸太, 村上隆介, 小原久典, 千代田達幸, 重田昌吾, 岡本愛光

    日本癌治療学会学術集会(Web)　62nd　2024

  21. SNNSの実装化により導かれる子宮頸癌治療の未来

    永井智之, 橋本栄文, 橋本千明, 藤田信弘, 海法道子, 重田昌吾, 島田宗昭, 新倉仁, 山田秀和

    SNNS研究会学術集会プログラム抄録集　26th　2024

  22. 子宮頸部腺系病変の診断におけるp16/Ki67二重染色の有用性

    石橋ますみ, 岡本聡, 宮原周子, 橋本千明, 重田昌吾, 島田宗昭, 島田宗昭

    日本臨床細胞学会雑誌(Web)　63　2024

    ISSN： 1882-7233

  23. 転移性卵巣腫瘍を契機に発見された大腸癌の2症例

    石橋ますみ, 影山咲子, 宮原周子, 渋谷祐介, 湊純子, 橋本千明, 重田昌吾, 島田宗昭, 島田宗昭

    Abstracts. Annual Symposium. Japanese Society for the Advancement of Women’s Imaging (CD-ROM)　25th　2024

  24. Y染色体成分を有するTurner症候群患者に発症した卵巣卵黄嚢腫瘍の1例

    毛利春希, 宮原周子, 清水孝規, 渋谷祐介, 石橋ますみ, 重田昌吾, 島田宗昭

    北日本産科婦人科学会総会・学術講演会プログラム・抄録集(Web)　71st　2024

  25. 【卵巣癌維持療法の日本人リアルワールドデータから見えてくるもの】進行・再発卵巣癌維持療法の治療成績と臨床背景に関する後方視的検討

    重田 昌吾, 島田 宗昭, 遠藤 俊, 橋本 栄文, 石橋 ますみ, 湊 純子, 渋谷 祐介, 清水 孝規, 栃木 実佳子, 萩原 達也, 徳永 英樹, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　65回　138-138　2023/07

    Publisher: (公社)日本婦人科腫瘍学会

  26. 子宮体癌における血漿メタボローム解析による新規バイオマーカーの探索

    萩原 達也, 島田 宗昭, 菱沼 英史, 李 賓, 久木元 詩央香, 橋本 栄文, 遠藤 俊, 清水 孝規, 湊 純子, 渋谷 祐介, 石橋 ますみ, 橋本 千明, 重田 昌吾, 徳永 英樹, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　65回　261-261　2023/07

    Publisher: (公社)日本婦人科腫瘍学会

  27. 子宮体癌の術前進行期評価における画像診断の有用性

    橋本 千明, 重田 昌吾, 久木元 詩央香, 栃木 実佳子, 橋本 栄文, 萩原 達也, 遠藤 俊, 清水 孝規, 湊 純子, 渋谷 祐介, 石橋 ますみ, 影山 咲子, 佐藤 友美, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　65回　265-265　2023/07

    Publisher: (公社)日本婦人科腫瘍学会

  28. Revisiting the Diagnostic Value of Risk of Ovarian Malignancy Algorithm(ROMA) for Differential Diagnosis of Epithelial Ovarian Cancer(タイトル和訳中)

    遠藤 俊, 重田 昌吾, 久木元 詩央香, 栃木 実佳子, 橋本 栄文, 萩原 達也, 清水 孝規, 湊 純子, 渋谷 祐介, 石橋 ますみ, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　65回　277-277　2023/07

    Publisher: (公社)日本婦人科腫瘍学会

  29. 再発卵巣癌に対するSchlafen11発現とPARP阻害剤の効果に関する検討

    堀川 翔太, 太田 剛, 奥井 陽介, 清野 学, 重田 昌吾, 徳永 英樹, 八重樫 伸生, 永瀬 智

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　65回　293-293　2023/07

    Publisher: (公社)日本婦人科腫瘍学会

  30. 経時的血中循環腫瘍DNA採血を行った卵巣癌患者8症例の検討

    渋谷 祐介, 重田 昌吾, 島田 宗昭, 菱沼 英史, 湊 敬道, 久木元 詩央香, 栃木 実佳子, 橋本 栄文, 萩原 達也, 遠藤 俊, 清水 孝規, 湊 純子, 橋本 千明, 石橋 ますみ, 徳永 英樹

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　65回　297-297　2023/07

    Publisher: (公社)日本婦人科腫瘍学会

  31. 妊娠を契機に発見された多房性嚢胞状変化を主体とした若年型顆粒膜細胞腫

    石橋 ますみ, 徳永 英樹, 後藤 恵, 湊 純子, 橋本 千明, 重田 昌吾, 永井 智之, 島田 宗昭, 山崎 有人, 渡辺 みか, 森谷 卓也, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　65回　305-305　2023/07

    Publisher: (公社)日本婦人科腫瘍学会

  32. 高齢の子宮体癌に対するリンパ節郭清の意義に関する検討

    湊 純子, 重田 昌吾, 栃木 実佳子, 橋本 栄文, 萩原 達也, 遠藤 俊, 清水 孝規, 渋谷 祐介, 橋本 千明, 石橋 ますみ, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　65回　329-329　2023/07

    Publisher: (公社)日本婦人科腫瘍学会

  33. Lenvatinib/Pembrolizumab併用療法を施行した進行・再発子宮体癌15症例の後方視的検討

    栃木 実佳子, 重田 昌吾, 橋本 栄文, 萩原 達也, 清水 孝規, 遠藤 俊, 湊 純子, 橋本 千明, 石橋 ますみ, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　65回　343-343　2023/07

    Publisher: (公社)日本婦人科腫瘍学会

  34. 傍大動脈リンパ節郭清術後に横隔膜交通症を発症した卵巣癌の一症例

    石橋 ますみ, 徳永 英樹, 橋本 栄文, 高橋 友梨, 重田 昌吾, 村上 康司, 渡邉 龍秋, 島田 宗昭, 八重樫 伸生

    産婦人科手術　(34)　155-155　2023/06

    Publisher: (株)メジカルビュー社

    ISSN： 0915-8375

  35. がんゲノム医療における超音波の役割 HBOC診療における超音波診断の可能性と限界

    湊 純子, 島田 宗昭, 栃木 実佳子, 渋谷 祐介, 橋本 千明, 石橋 ますみ, 重田 昌吾, 徳永 英樹, 八重樫 伸生

    超音波医学　50　(Suppl.)　S177-S177　2023/04

    Publisher: (公社)日本超音波医学会

    ISSN： 1346-1176

    eISSN： 1881-9311

  36. 子宮体癌における後腹膜リンパ節転移の術前評価に対する画像診断の有用性

    橋本 千明, 徳永 英樹, 久木元 詩央香, 栃木 実佳子, 萩原 達也, 橋本 栄文, 湊 純子, 渋谷 祐介, 石橋 ますみ, 重田 昌吾, 島田 宗昭, 八重樫 伸生

    日本産科婦人科学会雑誌　75　(臨増)　S-428　2023/02

    Publisher: (公社)日本産科婦人科学会

    ISSN： 0300-9165

  37. ペムブロリズマブ,レンバチニブ併用療法を施行した進行・再発子宮体癌12症例の後方視的検討

    栃木 実佳子, 重田 昌吾, 橋本 栄文, 萩原 達也, 清水 孝規, 遠藤 俊, 湊 純子, 橋本 千明, 石橋 ますみ, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本産科婦人科学会雑誌　75　(臨増)　S-521　2023/02

    Publisher: (公社)日本産科婦人科学会

    ISSN： 0300-9165

  38. 画像診断に苦慮した卵巣内膜症性嚢胞の一例

    石橋ますみ, 徳永英樹, 後藤恵, 橋本栄文, 湊敬道, 重田昌吾, 島田宗昭, 八重樫伸生

    日本エンドメトリオーシス学会学術講演会プログラム・抄録集　44th　2023

  39. 再発/持続性の卵巣癌,卵管癌又は原発性腹膜明細胞癌の患者を対象として選択的PI3Kα阻害剤CYH33の有効性及び安全性を検討する第II相非盲検多施設共同試験

    重田昌吾

    婦人科悪性腫瘍研究機構年次会議(総会)記録集　21st　2023

    ISSN： 2188-0123

  40. Successful R0 Resection of Two Metachronous Krukenberg Tumors from Gastric Cancer-A Case Report

    添田敏寛, 山村明寛, 田中直樹, 井本博文, 土屋尭裕, 永井智之, 重田昌吾, 渡邊裕文, 西條文人, 森川孝則, 大沼忍, 亀井尚, 海野倫明

    癌と化学療法　49　(13)　1832-1834　2022/12

    Publisher: (株)癌と化学療法社

    ISSN： 0385-0684

  41. 妊娠中・分娩後の適切なCIN管理 妊娠中の細胞診断における過小評価例の検討

    岡本 聡, 徳永 英樹, 石橋 ますみ, 重田 昌吾, 島田 宗昭, 渡邉 みか, 新倉 仁, 伊藤 潔, 八重樫 伸生

    日本臨床細胞学会雑誌　61　(Suppl.2)　412-412　2022/10

    Publisher: (公社)日本臨床細胞学会

    ISSN： 0387-1193

    eISSN： 1882-7233

  42. 細胞診レポートの質の管理と臨床医師とのコミュニケーション能力 適切な治療方針決定のために臨床医師が細胞診依頼で留意すべきこと

    石橋 ますみ, 岡本 聡, 重田 昌吾, 徳永 英樹, 島田 宗昭, 伊藤 潔, 八重樫 伸生

    日本臨床細胞学会雑誌　61　(Suppl.2)　458-458　2022/10

    Publisher: (公社)日本臨床細胞学会

    ISSN： 0387-1193

    eISSN： 1882-7233

  43. 【子宮体がんup to date】子宮体癌に対する最新薬物療法

    橋本 千明, 徳永 英樹, 重田 昌吾, 島田 宗昭

    産婦人科の実際　71　(11)　1367-1372　2022/10

    Publisher: 金原出版(株)

    ISSN： 0558-4728

  44. 子宮頸部円錐切除術における術中頸管細胞診の有用性に関する検証

    重田 昌吾, 橋本 千明, 石橋 ますみ, 岡本 聡, 徳永 英樹, 島田 宗昭, 伊藤 潔, 八重樫 伸生

    日本臨床細胞学会雑誌　61　(Suppl.2)　482-482　2022/10

    Publisher: (公社)日本臨床細胞学会

    ISSN： 0387-1193

    eISSN： 1882-7233

  45. 全ゲノム/全エキソーム解析による生殖細胞系列多型の探索 一般住民コホートにおけるBRCA遺伝子バリアントの探索及び結果の回付事業について(Exploration of BRCA1/2 gene variants in a general population cohort and return of genomic results to the participants)

    徳永 英樹, 安田 純, 島田 宗昭, 濱中 洋平, 重田 昌吾, 布施 昇男, 勝岡 史城, 荻島 創一, 山口 由美, 寳澤 篤, 川目 裕, 大根田 絹子, 青木 洋子, 山本 雅之, 八重樫 伸生

    日本癌学会総会記事　81回　S8-1　2022/09

    Publisher: (一社)日本癌学会

    ISSN： 0546-0476

  46. ワイドターゲットメタボロミクスによる子宮頸癌の診断および放射線感受性予測バイオマーカーの同定

    萩原 達也, 島田 宗昭, 橋本 栄文, 遠藤 俊, 清水 孝規, 宮原 周子, 湊 敬道, 湊 純子, 渋谷 祐介, 石橋 ますみ, 重田 昌吾, 橋本 千明, 永井 智之, 徳永 英樹, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　64回　190-190　2022/07

    Publisher: (公社)日本婦人科腫瘍学会

  47. チロシンキナーゼ受容体型蛋白TIE-1の卵巣癌に対する抗腫瘍効果の検討

    石橋 ますみ, 徳永 英樹, 重田 昌吾, 永井 智之, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　64回　194-194　2022/07

    Publisher: (公社)日本婦人科腫瘍学会

  48. MicroRNA-152/MMP10 Axisによる漿液性子宮内膜癌細胞の運動性の制御(MicroRNA-152/MMP10 Axis Regulates Endometrial Serous Carcinoma Cell Motility)

    重田 昌吾, 渡部 洋, 永瀬 智, 渋谷 祐介, 石橋 ますみ, 永井 智之, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　64回　199-199　2022/07

    Publisher: (公社)日本婦人科腫瘍学会

  49. 卵巣癌既発症のBRCA病的バリアント保持者に対する乳房サーベイランスの現状

    湊 純子, 島田 宗昭, 橋本 栄文, 萩原 達也, 湊 敬道, 橋本 千明, 石橋 ますみ, 重田 昌吾, 永井 智之, 徳永 英樹, 八重樫 伸生

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　64回　210-210　2022/07

    Publisher: (公社)日本婦人科腫瘍学会

  50. 【いま大きく変わりつつある子宮頸がんの診療】局所進行子宮頸がんの治療法に関する最近のエビデンス

    萩原 達也, 重田 昌吾, 島田 宗昭, 八重樫 伸生

    産婦人科の実際　71　(6)　599-604　2022/06

    Publisher: 金原出版(株)

    ISSN： 0558-4728

  51. リスク低減卵管卵巣摘出術待機中にIIIA1(ii)期の卵管癌を発症した遺伝性乳癌卵巣癌症候群の一例

    村川 真理弥, 湊 純子, 熊谷 奈津美, 萩原 達也, 橋本 栄文, 高橋 友梨, 栃木 実佳子, 橋本 千明, 石橋 ますみ, 重田 昌吾, 永井 智之, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    東北連合産科婦人科学会総会・学術講演会プログラム・抄録集　151回　59-59　2022/05

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  52. 子宮体癌再発との鑑別が困難であった後腹膜領域に発生した神経鞘腫の一例

    濱田 衣美子, 重田 昌吾, 橋本 栄文, 湊 敬道, 湊 純子, 橋本 千明, 石橋 ますみ, 永井 智之, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    東北連合産科婦人科学会総会・学術講演会プログラム・抄録集　151回　61-61　2022/05

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  53. 当院における遺伝性乳癌卵巣癌症候群に対するリスク低減卵管卵巣摘出術の経験

    湊 純子, 島田 宗昭, 萩原 達也, 橋本 栄文, 湊 敬道, 橋本 千明, 石橋 ますみ, 重田 昌吾, 永井 智之, 徳永 英樹, 八重樫 伸生

    日本産科婦人科学会雑誌　74　(臨増)　S-328　2022/02

    Publisher: (公社)日本産科婦人科学会

    ISSN： 0300-9165

  54. 広汎子宮全摘術実施症例におけるFIGO2018進行期分類IIIC1期の臨床病理学的検討

    橋本 千明, 湊 純子, 渋谷 祐介, 石橋 ますみ, 重田 昌吾, 永井 智之, 渡邉 善, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本産科婦人科学会雑誌　74　(臨増)　S-469　2022/02

    Publisher: (公社)日本産科婦人科学会

    ISSN： 0300-9165

  55. 進行卵巣癌における初回化学療法後の維持療法選択に関する後方視的検討

    橋本 栄文, 萩原 達也, 遠藤 俊, 清水 孝規, 湊 敬道, 湊 純子, 橋本 千明, 石橋 ますみ, 重田 昌吾, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本産科婦人科学会雑誌　74　(臨増)　S-496　2022/02

    Publisher: (公社)日本産科婦人科学会

    ISSN： 0300-9165

  56. がん遺伝子パネル検査の現状と課題

    萩原 達也, 重田 昌吾, 橋本 栄文, 湊 敬道, 湊 純子, 渋谷 祐介, 石橋 ますみ, 橋本 千明, 永井 智之, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本産科婦人科学会雑誌　74　(臨増)　S-336　2022/02

    Publisher: (公社)日本産科婦人科学会

    ISSN： 0300-9165

  57. 婦人科悪性腫瘍における直接経口抗凝固薬の使用下での静脈血栓塞栓症再発または抗凝固薬変更の予測モデル

    清水 孝規, 岩間 憲之, 徳永 英樹, 遠藤 俊, 宮原 周子, 土岐 麻実, 志賀 尚美, 石橋 ますみ, 重田 昌吾, 永井 智之, 島田 宗昭, 八重樫 伸生

    日本産科婦人科学会雑誌　74　(臨増)　S-516　2022/02

    Publisher: (公社)日本産科婦人科学会

    ISSN： 0300-9165

  58. Exploration of BRCA1/2 gene variants in a general population cohort and return of genomic results to the participants

    徳永英樹, 安田純, 島田宗昭, 濱中洋平, 重田昌吾, 布施昇男, 勝岡史城, 荻島創一, 荻島創一, 山口由美, 寳澤篤, 川目裕, 大根田絹子, 青木洋子, 山本雅之, 八重樫伸生

    日本癌学会学術総会抄録集(Web)　81st　2022

  59. 妊娠中の細胞診断における過小評価例の検討

    岡本聡, 徳永英樹, 石橋ますみ, 重田昌吾, 島田宗昭, 渡邉みか, 新倉仁, 伊藤潔, 八重樫伸生

    日本臨床細胞学会雑誌(Web)　61　2022

    ISSN： 1882-7233

  60. 適切な治療方針決定のために臨床医師が細胞診依頼で留意すべきこと

    石橋ますみ, 岡本聡, 重田昌吾, 徳永英樹, 島田宗昭, 伊藤潔, 八重樫伸生

    日本臨床細胞学会雑誌(Web)　61　2022

    ISSN： 1882-7233

  61. 症例数が限定された施設におけるロボット支援手術の普及と教育に関して

    永井智之, 湊純子, 橋本千明, 石橋ますみ, 重田昌吾, 渡邉善, 徳永英樹, 島田宗昭, 八重樫伸生

    日本ロボット外科学会学術集会プログラム・抄録集　14th　2022

  62. 安全なロボット支援手術を目指し合併症症例から学ぶ

    橋本千明, 永井智之, 湊純子, 渋谷祐介, 石橋ますみ, 重田昌吾, 渡邉善, 徳永英樹, 島田宗昭, 八重樫伸生

    日本ロボット外科学会学術集会プログラム・抄録集　14th　2022

  63. 全腹腔鏡下子宮全摘術後に臍部肥厚性瘢痕を合併した一例

    佐藤壮樹, 田邉康次郎, 重田昌吾, 西本光男, 新倉仁

    日本産科婦人科内視鏡学会学術講演会(Web)　61st　(Suppl.I)　272-272　2021/09

    Publisher: (一社)日本産科婦人科内視鏡学会

    ISSN： 1884-9938

    eISSN： 1884-5746

  64. 地方の非認定研修施設で専攻医が全腹腔鏡下子宮全摘術(TLH)を遂行するために必要な準備について

    佐藤壮樹, 西本光男, 木村翔太, 山口峻史, 重田昌吾, 田邉康次郎

    日本産科婦人科内視鏡学会学術講演会(Web)　61st　(Suppl.I)　366-366　2021/09

    Publisher: (一社)日本産科婦人科内視鏡学会

    ISSN： 1884-9938

    eISSN： 1884-5746

  65. 当院における腹腔鏡下筋腫核出術におけるin bag morcellation準備時間の推移と工夫

    遠藤 祐介, 田邉 康次郎, 重田 昌吾, 柏館 直子, 松浦 類, 石垣 展子, 武山 陽一, 新倉 仁

    北日本産科婦人科学会総会・学術講演会プログラム・抄録集　68回　79-79　2021/08

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  66. プロモドメインタンパク質を中心とした卵巣明細胞癌の新規個別化医療に向けた研究

    重田 昌吾

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　63回　130-130　2021/07

    Publisher: (公社)日本婦人科腫瘍学会

  67. 硬化性腹膜炎を伴う黄体化莢膜細胞腫の1例

    萩原 達也, 遠藤 祐介, 後藤 恵, 佐藤 壮樹, 西澤 圭織, 田邊 康次郎, 重田 昌吾, 松浦 類, 柏館 直子, 新倉 仁

    日本婦人科腫瘍学会学術講演会プログラム・抄録集　63回　255-255　2021/07

    Publisher: (公社)日本婦人科腫瘍学会

  68. 子宮頸癌にて広汎子宮全摘術後Stewart-Treves症候群を発症した1例

    村川 真理弥, 田邉 康次郎, 遠藤 祐介, 村川 東, 後藤 恵, 萩原 達也, 重田 昌吾, 柏舘 直子, 松浦 類, 石垣 展子, 武山 陽一, 新倉 仁

    東北連合産科婦人科学会総会・学術講演会プログラム・抄録集　149回　38-38　2021/06

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  69. 当院で子宮鏡手術をした帝王切開瘢痕症候群の不妊症3例

    西澤 圭織, 田邉 康次郎, 阿部 州雄, 遠藤 祐介, 後藤 恵, 佐藤 壮樹, 萩原 達也, 重田 昌吾, 松浦 類, 柏舘 直子, 石垣 展子, 武山 陽一, 新倉 仁

    東北連合産科婦人科学会総会・学術講演会プログラム・抄録集　149回　59-59　2021/06

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  70. 子宮筋腫に対する子宮動脈塞栓術12例の検討

    佐藤 壮樹, 田邉 康次郎, 遠藤 祐介, 後藤 恵, 西澤 圭織, 萩原 達也, 重田 昌吾, 柏舘 直子, 松浦 類, 石垣 展子, 武山 陽一, 新倉 仁

    東北連合産科婦人科学会総会・学術講演会プログラム・抄録集　149回　59-59　2021/06

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  71. 術後再発低リスク子宮頸癌IB-IIA期1,143例の臨床病理学的検討

    辻 圭太, 島田 宗昭, 重田 昌吾, 徳永 英樹, 山口 聡, 竹島 信宏, 中西 透, 齋藤 俊章, 八重樫 伸生, 三上 幹男, 杉山 徹

    日本産科婦人科学会雑誌　73　(臨増)　S-309　2021/03

    Publisher: (公社)日本産科婦人科学会

    ISSN： 0300-9165

  72. 術後再発中リスク子宮頸癌IB-IIA期1,657例の臨床病理学的検討

    重田 昌吾, 辻 圭太, 島田 宗昭, 永井 智之, 徳永 英樹, 上浦 祥司, 岩田 卓, 横田 治重, 三上 幹男, 杉山 徹

    日本産科婦人科学会雑誌　73　(臨増)　S-309　2021/03

    Publisher: (公社)日本産科婦人科学会

    ISSN： 0300-9165

  73. 子宮頸癌IIA期425例の臨床病理学的検討

    宮原 周子, 島田 宗昭, 重田 昌吾, 辻 圭太, 永井 智之, 徳永 英樹, 佐藤 豊実, 片渕 秀隆, 児玉 省二, 八重樫 伸生, 三上 幹男, 杉山 徹

    日本産科婦人科学会雑誌　73　(臨増)　S-309　2021/03

    Publisher: (公社)日本産科婦人科学会

    ISSN： 0300-9165

  74. 卵巣嚢腫茎捻転との鑑別が困難であった腸間膜嚢胞の一例

    後藤 恵, 田邉 康次郎, 村川 真理弥, 村川 東, 田邉 昌平, 萩原 達也, 重田 昌吾, 新倉 仁

    日本産科婦人科内視鏡学会雑誌　37　(2)　93-96　2021

    Publisher: (一社)日本産科婦人科内視鏡学会

    ISSN： 1884-9938

    eISSN： 1884-5746

  75. 本邦におけるHPV陰性若年子宮頸がん患者の特性 MINT study

    佐々木 里美, 重田 昌吾, 松本 光司, 吉川 裕之, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　39　(1)　277-277　2021/01

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  76. 子宮体癌における血漿メタボローム解析によるバイオマーカーの探索

    辻 圭太, 島田 宗昭, 菱沼 英史, 重田 昌吾, 李 賓, 宮原 周子, 土岐 麻実, 工藤 敬, 徳永 英樹, 小柴 生造, 木下 賢吾, 山本 雅之, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　39　(1)　297-297　2021/01

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  77. がん代謝を標的とした卵巣癌におけるバイオマーカーの探索

    工藤 敬, 島田 宗昭, 菱沼 英史, 重田 昌吾, 李 賓, 宮原 周子, 土岐 麻実, 辻 圭太, 徳永 英樹, 小柴 生造, 木下 賢吾, 山本 雅之, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　39　(1)　298-298　2021/01

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  78. 静脈血栓塞栓症に対する直接経口抗凝固薬の治療効果についての検討

    清水 孝規, 徳永 英樹, 鈴木 一誠, 宮原 周子, 土岐 麻実, 工藤 敬, 橋本 千明, 重田 昌吾, 辻 圭太, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　39　(1)　316-316　2021/01

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  79. 婦人科領域の神経内分泌腫瘍に対するVAC-PE交代療法の後方視的検討

    重田 昌吾, 徳永 英樹, 島田 宗昭, 辻 圭太, 岡本 聡, 橋本 千明, 土岐 麻実, 工藤 敬, 宮原 周子, 清水 孝規, 高野 忠夫, 伊藤 潔, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　39　(1)　434-434　2021/01

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  80. 異なる臨床経過を辿ったAggressive angiomyxoma 4症例の検討

    永井 智之, 徳永 英樹, 清水 孝規, 宮原 周子, 工藤 敬, 土岐 麻実, 重田 昌吾, 辻 圭太, 國島 温志, 植草 良輔, 河合 要介, 梅村 康太, 河井 通泰, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　39　(1)　437-437　2021/01

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  81. 卵巣癌における低侵襲手術 卵巣癌におけるMISの可能性

    永井 智之, 河合 要介, 梅村 康太, 河井 通泰, 重田 昌吾, 辻 圭太, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本産科婦人科内視鏡学会雑誌　36　(Suppl.I)　[WS6-1]　2020/11

    Publisher: (一社)日本産科婦人科内視鏡学会

    ISSN： 1884-9938

    eISSN： 1884-5746

  82. Functional analysis of ZFHX4 as a novel therapeutic target in ovarian cancer

    Yoshiko Oyama, Shogo Shigeta, Keita Tsuji, Hideki Tokunaga, Muneaki Shimada, Nobuo Yaegashi

    CANCER RESEARCH　80　(16)　2020/08

    DOI： 10.1158/1538-7445.AM2020-1285 　

    ISSN： 0008-5472

    eISSN： 1538-7445

  83. 【やさしくわかる 産科婦人科検査マスターブック】(第2章)婦人科腫瘍分野 腹水細胞診 Invited

    重田 昌吾, 岡本 聡, 伊藤 潔

    産科と婦人科　87　(Suppl.)　109-112　2020/03

    Publisher: (株)診断と治療社

    ISSN： 0386-9792

  84. 腹式広汎子宮頸部摘出術後に左卵管腟内脱出を認め腹腔鏡下左卵管切除術を施行した一例 Peer-reviewed

    吉田 悠人, 徳永 英樹, 重田 昌吾, 櫻田 尚子, 志賀 尚美, 永井 智之, 島田 宗昭, 八重樫 伸生

    日本産科婦人科内視鏡学会雑誌　35　(2)　372-376　2019/12

    Publisher: (一社)日本産科婦人科内視鏡学会

    ISSN： 1884-9938

    eISSN： 1884-5746

  85. Bevacizumabを用いた術前補助化学療法中に小腸穿孔を起こした進行卵巣癌の一例

    高橋 靖乃, 宮原 周子, 齋藤 淳一, 重田 昌吾, 辻 圭太, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    北日本産科婦人科学会総会・学術講演会プログラム・抄録集　67回　52-52　2019/09

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  86. 当院におけるロボット支援腹腔鏡下広汎子宮全摘術の短期成績の検討

    宮原 周子, 湊 敬道, 佐々木 里美, 大山 喜子, 土岐 麻美, 重田 昌吾, 辻 圭太, 渡邉 善, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本産科婦人科内視鏡学会雑誌　35　(Suppl.I)　127-127　2019/08

    Publisher: (一社)日本産科婦人科内視鏡学会

    ISSN： 1884-9938

    eISSN： 1884-5746

  87. 当院でのロボット支援腹腔鏡下広汎子宮全摘術における卵巣移動についての工夫

    重田 昌吾, 徳永 英樹, 渡邉 善, 辻 圭太, 石橋 ますみ, 土岐 麻美, 工藤 沙織, 島田 宗昭, 菅原 準一, 八重樫 伸生

    日本産科婦人科内視鏡学会雑誌　35　(Suppl.I)　127-127　2019/08

    Publisher: (一社)日本産科婦人科内視鏡学会

    ISSN： 1884-9938

    eISSN： 1884-5746

  88. 子宮頸癌進行期分類FIGO2018の検証 IB1/IB2期(FIGO2018)の臨床病理学的検討

    辻 圭太, 島田 宗昭, 重田 昌吾, 徳永 英樹, 山口 聡, 竹島 信宏, 中西 透, 齋藤 俊章, 八重樫 伸生, 三上 幹男, 杉山 徹

    日本婦人科腫瘍学会雑誌　37　(3)　444-444　2019/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  89. 子宮頸部異型腺細胞の細胞診判定におけるp16INK4a/Ki67二重免疫染色の有用性

    土岐 麻実, 徳永 英樹, 岡本 聡, 石橋 ますみ, 重田 昌吾, 辻 圭太, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　37　(3)　449-449　2019/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  90. 子宮頸癌におけるOSNA(one-step nucleic acid amplification)法の性能評価

    岡本 聡, 新倉 仁, 土岐 麻実, 辻 圭太, 重田 昌吾, 石橋 ますみ, 徳永 英樹, 大山 喜子, 佐々木 里美, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　37　(3)　469-469　2019/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  91. 進行・再発子宮頸癌に対するベバシズマブ維持療法の有効性と安全性の検討

    佐々木 里美, 徳永 英樹, 湊 敬道, 大山 喜子, 土岐 麻実, 橋本 千明, 重田 昌吾, 辻 圭太, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　37　(3)　480-480　2019/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  92. 子宮体癌I期における腹腔細胞診の意義

    大山 喜子, 石橋 ますみ, 岡本 聡, 宮原 周子, 湊 敬道, 佐々木 里美, 土岐 麻実, 重田 昌吾, 辻 圭太, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　37　(3)　511-511　2019/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  93. 進行卵巣癌に対する当院の手術療法の後方視的な検討

    湊 敬道, 徳永 英樹, 宮原 周子, 大山 喜子, 佐々木 里美, 土岐 麻実, 重田 昌吾, 辻 圭太, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　37　(3)　532-532　2019/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  94. 急速に進行し、治療に難渋した卵巣卵黄嚢腫瘍IVB期の1例

    宮原 周子, 辻 圭太, 熊谷 奈津美, 平賀 裕章, 品川 真澄, 重田 昌吾, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　37　(3)　572-572　2019/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  95. 急速に進行し、治療に難渋した卵巣卵黄嚢腫瘍IVB期の1例

    宮原 周子, 辻 圭太, 品川 真澄, 重田 昌吾, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    東北連合産科婦人科学会総会・学術講演会プログラム・抄録集　147回　45-45　2019/05

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  96. 多発直腸穿孔により持続ドレナージを要した子宮頸癌(CCRT後)の一例

    西澤 圭織, 佐々木 里美, 湊 敬道, 石橋 ますみ, 重田 昌吾, 島田 宗昭, 工藤 沙織, 土岐 麻美, 辻 圭太, 徳永 英樹, 八重樫 伸生

    東北連合産科婦人科学会総会・学術講演会プログラム・抄録集　147回　59-59　2019/05

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  97. 進行卵巣癌を疑われた壁外発育型大腸癌の一例

    湊 敬道, 徳永 英樹, 西澤 圭織, 工藤 沙織, 石橋 ますみ, 重田 昌吾, 島田 宗昭, 八重樫 伸生

    東北連合産科婦人科学会総会・学術講演会プログラム・抄録集　147回　61-61　2019/05

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  98. Bevacizumab併用化学療法にて小腸穿通を認めた再発卵巣癌の一例

    熊谷 奈津美, 辻 圭太, 宮原 周子, 品川 真澄, 重田 昌吾, 徳永 英樹, 島田 宗昭, 八重樫 伸生

    東北連合産科婦人科学会総会・学術講演会プログラム・抄録集　147回　66-66　2019/05

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  99. 当院におけるオラパリブ維持療法の使用経験

    重田 昌吾, 徳永 英樹, 土岐 麻美, 辻 圭太, 島田 宗昭, 八重樫 伸生

    東北連合産科婦人科学会総会・学術講演会プログラム・抄録集　147回　67-67　2019/05

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  100. 婦人科癌におけるセンチネルリンパ節転移診断の現状とOSNA法の性能評価

    土岐麻実, 新倉仁, 岡本聡, 永井智之, 重田昌吾, 辻圭太, 徳永英樹, 島田宗昭, 八重樫伸生

    SNNS研究会学術集会プログラム抄録集　21st　2019

  101. チロシンキナーゼ受容体TIE-1は卵巣癌におけるヌクレオチド除去修復を促進することによりプラチナ製剤抵抗性を媒介する(Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer)

    Ishibashi Masumi, Toyoshima Masafumi, Zhang Xuewei, Minato Junko, Shigeta Shogo, Kitatani Kazuyuki, Yaegashi Nobuo

    The Journal of Obstetrics and Gynaecology Research　43　(12)　1939-1939　2017/12

    Publisher: John Wiley & Sons Australia, Ltd

    ISSN： 1341-8076

  102. 【がん転移学(上)-がん転移のメカニズムと治療戦略:その基礎と臨床-】 がん転移学の基礎研究 がんの発生進展の分子機構 卵巣癌の分子機構

    渋谷 祐介, 重田 昌吾, 伊藤 潔, 北谷 和之, 八重樫 伸生

    日本臨床　75　(増刊8 がん転移学(上))　236-240　2017/11

    Publisher: (株)日本臨床社

    ISSN： 0047-1852

  103. 卵巣癌に対するセラミドナノリポソーム製剤の抗腫瘍作用

    張雪薇, 北谷和之, 北谷和之, 豊島将文, 石橋ますみ, 臼井利典, 湊純子, 重田昌吾, KESTER Mark, 八重樫伸生, 八重樫伸生

    婦人科がんバイオマーカー研究会学術集会プログラム・抄録集　5th　2017

  104. 卵巣がん転移制御へのセラミド合成酵素2の関与

    北谷和之, 北谷和之, 張雪薇, 臼井利典, 豊島将文, 重田昌吾, 石橋ますみ, 小木曽英夫, 岡崎俊朗, 八重樫伸生, 八重樫伸生

    婦人科がんバイオマーカー研究会学術集会プログラム・抄録集　5th　2017

  105. 卵巣癌におけるc-mycと合成致死作用を持つ治療標的分子の探索

    湊純子, 豊島将文, 北谷和之, 重田昌吾, 石橋ますみ, 八重樫伸生

    婦人科がんバイオマーカー研究会学術集会プログラム・抄録集　5th　2017

  106. 子宮体癌のセンチネルリンパ節生検における捺印細胞診の診断精度についての検討

    佐藤 いずみ, 岡本 聡, 新倉 仁, 重田 昌吾, 橋本 千明, 辻 圭太, 徳永 英樹, 豊島 将文, 三浦 弘守, 渡部 みか, 八重樫 伸生

    日本臨床細胞学会雑誌　55　(Suppl.2)　475-475　2016/10

    Publisher: (公社)日本臨床細胞学会

    ISSN： 0387-1193

    eISSN： 1882-7233

  107. フローサイトメトリーを利用した腹水細胞診断法のパイロットスタディ

    徳永 英樹, 岡本 聡, 渡部 洋, 重田 昌吾, 辻 圭太, 大槻 愛, 海法 道子, 豊島 将文, 新倉 仁, 八重樫 伸生

    日本臨床細胞学会雑誌　55　(Suppl.2)　532-532　2016/10

    Publisher: (公社)日本臨床細胞学会

    ISSN： 0387-1193

    eISSN： 1882-7233

  108. セラミド合成酵素2による癌転移制御への関与

    北谷 和之, 張 雪薇, 臼井 利典, 豊島 将文, 重田 昌吾, マヒ・イギズ, 湊 純子, 石橋 ますみ, 小木曽 英夫, 岡崎 俊朗, 八重樫 伸生

    日本生化学会大会プログラム・講演要旨集　89回　[3P-305]　2016/09

    Publisher: (公社)日本生化学会

  109. セラミドナノリポソームによるネクロプトーシスの誘導

    張 雪薇, 豊島 将文, 石橋 ますみ, 臼井 利典, 湊 純子, 重田 昌吾, マーク・ケスター, 北谷 和之, 八重樫 伸生

    日本生化学会大会プログラム・講演要旨集　89回　[3P-078]　2016/09

    Publisher: (公社)日本生化学会

  110. 当院におけるロボット支援腹腔鏡下広汎子宮全摘術の検討

    橋本 千明, 新倉 仁, 辻 圭太, 重田 昌吾, 石橋 ますみ, 渡邉 善, 徳永 英樹, 海法 道子, 伊藤 潔, 八重樫 伸生

    日本産科婦人科内視鏡学会雑誌　32　(Suppl.I)　212-212　2016/08

    Publisher: (一社)日本産科婦人科内視鏡学会

    ISSN： 1884-9938

    eISSN： 1884-5746

  111. 子宮体がん・卵巣がん治療ガイドライン 検証・問題点・今後 子宮体がん治療ガイドライン 検証・問題点・今後

    重田 昌吾, 永瀬 智, 高橋 史朗, 三上 幹男, 八重樫 伸生, 宇田川 康博, 片渕 秀隆

    日本婦人科腫瘍学会雑誌　34　(3)　340-340　2016/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  112. 外陰部Eccrine porocarcinomaの一例

    藤峯 絢子, 豊島 将文, 重田 昌吾, 土岐 麻美, 久野 貴司, 渡邉 みか, 新倉 仁, 八重樫 伸生

    東北連合産科婦人科学会総会・学術講演会プログラム・抄録集　141回　78-78　2016/06

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  113. 当院におけるロボット支援腹腔鏡下子宮体癌手術の検討

    橋本 千明, 新倉 仁, 渡邊 善, 城 伶史, 渋谷 祐介, 櫻田 尚子, 佐藤 いずみ, 重田 昌吾, 辻 圭太, 豊島 将文, 徳永 英樹, 海法 道子, 高野 忠夫, 伊藤 潔, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　34　(3)　428-428　2016/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  114. 当院におけるペグフィルグラスチムの使用経験

    城 伶史, 徳永 英樹, 渡部 洋, 土岐 麻実, 渋谷 祐介, 湊 純子, 櫻田 尚子, 佐藤 いずみ, 重田 昌吾, 辻 圭太, 豊島 将文, 新倉 仁, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　34　(3)　488-488　2016/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  115. 婦人科癌性腹水におけるトリアムシノロンアセトニド腹腔内投与の有効性

    土岐 麻実, 新倉 仁, 城 伶史, 湊 純子, 渋谷 祐介, 櫻田 尚子, 橋本 千明, 重田 昌吾, 佐藤 いずみ, 辻 圭太, 徳永 英樹, 豊島 将文, 渡部 洋, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　34　(3)　507-507　2016/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  116. 卵巣がん細胞に対するセラミドナノリポソームの抗腫瘍効果 ネクロプトーシスの誘導

    張 雪薇, 豊島 将文, 石橋 ますみ, 臼井 利典, 湊 純子, 重田 昌吾, Kester Mark, 八重樫 伸生, 北谷 和之

    脂質生化学研究　58　68-69　2016/05

    Publisher: 日本脂質生化学会

    ISSN： 0285-1520

  117. セラミド合成酵素による癌転移制御

    北谷 和之, 張 雪薇, 臼井 利典, 豊島 将文, 重田 昌吾, Egiz Mahy, 湊 純子, 石橋 ますみ, 小木曽 英夫, 岡崎 俊朗, 八重樫 伸生

    脂質生化学研究　58　182-182　2016/05

    Publisher: 日本脂質生化学会

    ISSN： 0285-1520

  118. An advanced Sertoli-Leydig cell tumor with positive peritoneal cytology:&mdash;A case report&mdash; Peer-reviewed

    SHIGETA Shogo, TOKUNAGA Hideki, TSUJI Keita, OKAMOTO Satoshi, NIIKURA Hitoshi, ITO Kiyoshi, WATANABE Mika, YAEGASHI Nobuo

    The Journal of the Japanese Society of Clinical Cytology　55　(2)　123-128　2016/03

    Publisher: The Japanese Society of Clinical Cytology

    ISSN： 0387-1193

    eISSN： 1882-7233

  119. 大規模siRNAスクリーニングを用いたシスプラチン抵抗性卵巣がんに対する新たな分子標的の検討

    石橋ますみ, 豊島将文, 張雪薇, 湊純子, 重田昌吾, 臼井利典, 北谷和之, 北谷和之, 八重樫伸生

    婦人科がんバイオマーカー研究会学術集会プログラム・抄録集　4th　2016

  120. 卵巣がん転移に関わるセラミド生成代謝酵素

    北谷和之, 北谷和之, 張雪薇, 臼井利典, 豊島将文, 重田昌吾, 石橋ますみ, 小木曽英夫, 岡崎俊朗, 八重樫伸生, 八重樫伸生

    婦人科がんバイオマーカー研究会学術集会プログラム・抄録集　4th　2016

  121. フローサイトメトリーを利用した腹水細胞診断法のパイロットスタディ

    徳永英樹, 岡本聡, 渡部洋, 渡部洋, 重田昌吾, 辻圭太, 大槻愛, 海法道子, 豊島将文, 新倉仁, 八重樫伸生

    日本臨床細胞学会雑誌(Web)　55　2016

    ISSN： 1882-7233

  122. 腹水中にセルトリ細胞様腫瘍細胞および異所性成分由来の細胞を認めた進行セルトリ・ライディッヒ細胞腫の 1 例

    重田昌吾, 徳永英樹, 辻圭太, 岡本聡, 新倉仁, 伊藤潔, 渡辺みか, 八重樫伸生

    日本臨床細胞学会雑誌(Web)　55　(2)　2016

    ISSN： 1882-7233

  123. 子宮体癌のセンチネルリンパ節生検における捺印細胞診の診断精度についての検討

    佐藤いずみ, 岡本聡, 新倉仁, 重田昌吾, 橋本千明, 辻圭太, 徳永英樹, 豊島将文, 三浦弘守, 渡部みか, 八重樫伸生

    日本臨床細胞学会雑誌(Web)　55　2016

    ISSN： 1882-7233

  124. ISP-12-3 Transferrin is involved in the carcinogenesis of high-grade serous ovarian cancer by facilitating the DNA double-strand breaks via transferrin receptor 1 in fallopian tube(Group 12 Ovarian Cancer 1,International Session Poster) :

    Shigeta Shogo, Toyoshima Masafumi, Kitatani Kazuyuki, Ishibashi Masumi, Minato Junko, Yaegashi Nobuo

    68　(2)　510-510　2016

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  125. IS-AC-1-1 Casein kinase I epsilon is a novel molecular target for c-Myc driven ovarian cancers(Group 1 Oncology 1,International Session Award Candidate) :

    Toyoshima Masafumi, Kitatani Kazuyuki, Shigeta Shogo, Ishibashi Masumi, Minato Junko, Yaegashi Nobuo

    68　(2)　455-455　2016

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  126. 2)JSOG腫瘍登録データを用いた子宮体がん・卵巣がん治療動向 : 子宮体がん(JSOG婦人科腫瘍委員会 JSGOガイドライン委員会共同企画,公益社団法人日本産科婦人科学会第68回学術講演会)

    重田 昌吾, 永瀬 智, 三上 幹男, 八重樫 伸生, 宇田川 康博, 片渕 秀隆

    日本産科婦人科學會雜誌　68　(2)　443-443　2016

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  127. IS-MW-4-2 Clinical significance of sentinel lymph node metastases detected by ultrastaging of three different methods in endometrial cancer(Group 4 Oncology 2,International Session Mini Workshop) :

    Okamoto Satoshi, Niikura Hitoshi, Nagai Tomoyuki, Shigeta Shogo, Tsuji Keita, Sato Izumi, Hashimoto Chiaki, Tokunaga Hideki, Takano Tadao, Ito Kiyoshi, Watanabe Yoh, Yaegashi Nobuo

    68　(2)　473-473　2016

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  128. ISP-3-9 Outcome of minimally invasive surgery by using sentinel lymph node biopsy in cervical cancer(Group 3 Cervical Cancer 2,International Session Poster) :

    Toki Asami, Niikura Hitoshi, Okamoto Satoshi, Hashimoto Chiaki, Sato Izumi, Shigeta Shogo, Tsuji Keita, Tokunaga Hideki, Takano Tadao, Ito Kiyoshi, Watanabe Yoh, Yaegashi Nobuo

    68　(2)　486-486　2016

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  129. 【婦人科領域のRare Tumorの取り扱い】 子宮平滑筋肉腫

    高野 忠夫, 辻 圭太, 重田 昌吾, 橋本 千明, 佐藤 いずみ, 櫻田 尚子, 渋谷 祐介, 城 伶史, 湊 純子

    産婦人科の実際　65　(1)　9-18　2016/01

    Publisher: 金原出版(株)

    ISSN： 0558-4728

  130. P2-7-8 当科での子宮肉腫に対するIAP治療の後方視的検討(Group7 子宮体部腫瘍・ホルモン治療・化学療法,一般演題,公益社団法人日本産科婦人科学会第68回学術講演会)

    城 伶史, 徳永 英樹, 渡部 洋, 櫻田 尚子, 佐藤 いずみ, 重田 昌吾, 辻 圭太, 橋本 千明, 豊島 将文, 新倉 仁, 伊藤 潔, 八重樫 伸生

    日本産科婦人科學會雜誌　68　(2)　639-639　2016

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  131. 子宮腟部細胞診ASC-Hの検討

    城 伶史, 徳永 英樹, 岡本 聡, 湊 純子, 佐藤 いずみ, 重田 昌吾, 辻 圭太, 橋本 千明, 田中 創太, 志賀 尚美, 海法 道子, 伊藤 潔, 渡部 洋, 新倉 仁, 八重樫 伸生

    日本臨床細胞学会雑誌　54　(Suppl.2)　545-545　2015/10

    Publisher: (公社)日本臨床細胞学会

    ISSN： 0387-1193

    eISSN： 1882-7233

  132. 卵巣ブレンナー腫瘍の悪性度による細胞学的検討

    湊 純子, 徳永 英樹, 岡本 聡, 城 伶史, 佐藤 いずみ, 橋本 千明, 重田 昌吾, 辻 圭太, 田中 創太, 志賀 尚美, 海法 道子, 伊藤 潔, 渡部 洋, 新倉 仁, 八重樫 伸生

    日本臨床細胞学会雑誌　54　(Suppl.2)　565-565　2015/10

    Publisher: (公社)日本臨床細胞学会

    ISSN： 0387-1193

    eISSN： 1882-7233

  133. 子宮頸部原発骨肉腫の1例

    辻 圭太, 徳永 英樹, 湊 純子, 重田 昌吾, 佐藤 いずみ, 橋本 千明, 田中 創太, 志賀 尚美, 海法 道子, 岡本 聡, 高野 忠夫, 新倉 仁, 伊藤 潔, 渡部 洋, 八重樫 伸生

    日本臨床細胞学会雑誌　54　(Suppl.2)　656-656　2015/10

    Publisher: (公社)日本臨床細胞学会

    ISSN： 0387-1193

    eISSN： 1882-7233

  134. 腹水中に腫瘍細胞が出現した腟原発悪性黒色腫の一例

    重田 昌吾, 城 伶史, 湊 純子, 橋本 千明, 佐藤 いずみ, 辻 圭太, 田中 創太, 志賀 尚美, 海法 道子, 徳永 英樹, 岡本 聡, 新倉 仁, 伊藤 潔, 渡部 洋, 八重樫 伸生

    日本臨床細胞学会雑誌　54　(Suppl.2)　666-666　2015/10

    Publisher: (公社)日本臨床細胞学会

    ISSN： 0387-1193

    eISSN： 1882-7233

  135. 子宮体癌に対する腹腔鏡下子宮悪性腫瘍手術におけるセンチネルリンパ節生検の検討

    橋本 千明, 新倉 仁, 辻 圭太, 重田 昌吾, 渡邉 善, 徳永 英樹, 海法 道子, 宇都宮 裕貴, 伊藤 潔, 八重樫 伸生

    日本産科婦人科内視鏡学会雑誌　31　(Suppl.I)　253-253　2015/08

    Publisher: (一社)日本産科婦人科内視鏡学会

    ISSN： 1884-9938

    eISSN： 1884-5746

  136. 婦人科腫瘍の診断 OSNA法による術中センチネルリンパ節転移診断の妥当性の検証

    岡本 聡, 新倉 仁, 永井 智之, 田中 創太, 辻 圭太, 重田 昌吾, 佐藤 いずみ, 橋本 千明, 櫻田 尚子, 城 伶史, 長谷川 純子, 大槻 愛, 徳永 英樹, 海法 道子, 高野 忠夫, 伊藤 潔, 渡部 洋, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　33　(3)　529-529　2015/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  137. 多中心性intraepithelial carcinomaの一例

    徳永 英樹, 新倉 仁, 岡本 聡, 湊 純子, 城 伶史, 櫻田 尚子, 橋本 千明, 佐藤 いずみ, 重田 昌吾, 辻 圭太, 大槻 愛, 田中 創太, 海法 道子, 高野 忠夫, 渡部 洋, 伊藤 潔, 渡辺 みか, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　33　(3)　572-572　2015/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  138. 後腹膜に発生した扁平上皮癌の2例

    城 伶史, 徳永 英樹, 渡部 洋, 櫻田 尚子, 佐藤 いずみ, 重田 昌吾, 辻 圭太, 橋本 千明, 大槻 愛, 田中 創太, 海法 道子, 岡本 聡, 高野 忠夫, 新倉 仁, 伊藤 潔, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　33　(3)　574-574　2015/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  139. 当院での腟悪性黒色腫症例の臨床的検討

    櫻田 尚子, 新倉 仁, 城 伶史, 佐藤 いずみ, 橋本 千明, 重田 昌吾, 辻 圭太, 田中 創太, 海法 道子, 徳永 英樹, 岡本 聡, 伊藤 潔, 渡部 洋, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　33　(3)　626-626　2015/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  140. 日本人女性における食物摂取と子宮体部類内膜腺癌発症リスクについての症例対照研究

    重田 昌吾, 永瀬 智, 高山 真, 豊島 将文, 宇都宮 裕貴, 菅原 準一, 伊藤 潔, 八重樫 伸生

    北海道産科婦人科学会会誌　59　(1)　163-163　2015/03

    Publisher: 北海道産科婦人科学会

    ISSN： 0367-6277

  141. 化学療法を先行させた子宮体癌IVB期症例に対する検討

    永井 智之, 永瀬 智, 重田 昌吾, 辻 圭太, 佐藤 いずみ, 田中 創太, 海法 道子, 高野 忠夫, 新倉 仁, 伊藤 潔, 八重樫 伸生

    北海道産科婦人科学会会誌　59　(1)　177-178　2015/03

    Publisher: 北海道産科婦人科学会

    ISSN： 0367-6277

  142. 腹水中に腫瘍細胞が出現した腟原発悪性黒色腫の一例

    重田昌吾, 城伶史, 湊純子, 橋本千明, 佐藤いずみ, 辻圭太, 田中創太, 田中創太, 志賀尚美, 海法道子, 徳永英樹, 岡本聡, 新倉仁, 伊藤潔, 伊藤潔, 渡部洋, 渡部洋, 八重樫伸生

    日本臨床細胞学会雑誌(Web)　54　2015

    ISSN： 1882-7233

  143. 子宮腟部細胞診ASC-Hの検討

    城伶史, 徳永英樹, 岡本聡, 湊純子, 佐藤いづみ, 重田昌吾, 辻圭太, 橋本千明, 田中創太, 志賀尚美, 海法道子, 伊藤潔, 渡部洋, 新倉仁, 八重樫伸生

    日本臨床細胞学会雑誌(Web)　54　2015

    ISSN： 1882-7233

  144. 子宮頸部原発骨肉腫の1例

    辻圭太, 徳永英樹, 湊純子, 重田昌吾, 佐藤いずみ, 橋本千明, 田中創太, 志賀尚美, 海法道子, 岡本聡, 高野忠夫, 高野忠夫, 新倉仁, 伊藤潔, 伊藤潔, 渡部洋, 八重樫伸生

    日本臨床細胞学会雑誌(Web)　54　2015

    ISSN： 1882-7233

  145. 卵巣ブレンナー腫瘍の悪性度による細胞学的検討

    湊純子, 徳永英樹, 岡本聡, 城伶史, 佐藤いずみ, 橋本千明, 重田昌吾, 辻圭太, 田中創太, 志賀尚美, 海法道子, 伊藤潔, 渡部洋, 新倉仁, 八重樫伸生

    日本臨床細胞学会雑誌(Web)　54　2015

    ISSN： 1882-7233

  146. P1-9-5 月経血や卵胞液に含まれるトランスフェリンは1型トランスフェリン受容体を介して卵管上皮細胞におけるDNA二重鎮切断を誘導,増幅する(Group9 卵巣腫瘍 基礎3,一般演題,公益社団法人日本産科婦人科学会第67回学術講演会)

    重田 昌吾, 豊島 将文, 北谷 和之, 石橋 ますみ, 八重樫 伸生

    日本産科婦人科學會雜誌　67　(2)　554-554　2015

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  147. セラミドによる細胞運動調節 セラミドリポソームの抗播種転移薬としての可能性

    北谷 和之, 豊島 将文, 臼井 利典, 重田 昌吾, 石橋 ますみ, 永瀬 智, 八重樫 伸生

    脂質生化学研究　56　165-165　2014/05

    Publisher: 日本脂質生化学会

    ISSN： 0285-1520

  148. P3-46-1 子宮体癌4B期症例に対する治療法の検討(Group 143 子宮体部腫瘍・予後2,一般演題,公益社団法人日本産科婦人科学会第66回学術講演会)

    永井 智之, 永瀬 智, 重田 昌吾, 辻 圭太, 佐藤 いずみ, 田中 創太, 海法 道子, 徳永 英樹, 高野 忠夫, 新倉 仁, 渡部 洋, 八重樫 伸生

    日本産科婦人科學會雜誌　66　(2)　887-887　2014

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  149. P2-56-1 卵巣明細胞腺癌における治療標的分子としてのプラスミノーゲン活性化抑制因子PAI-1に関する検討(Group 94 卵巣腫瘍・基礎5,一般演題,公益社団法人日本産科婦人科学会第66回学術講演会)

    増子 さつき, 豊島 将文, 北谷 和之, 重田 昌吾, 石橋 ますみ, 八重樫 伸生

    日本産科婦人科學會雜誌　66　(2)　743-743　2014

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  150. P1-15-4 大規模siRNAスクリーニングを用いた卵巣がんのシスプラチン抵抗性を克服する分子標的の検討(Group 15 卵巣腫瘍・基礎2,一般演題,公益社団法人日本産科婦人科学会第66回学術講演会)

    石橋 ますみ, 豊島 将文, 北谷 和之, 増子 さつき, 重田 昌吾, 八重樫 伸生

    日本産科婦人科學會雜誌　66　(2)　510-510　2014

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  151. P1-14-6 セラミドによる細胞運動性の調節 : セラミドリポソームの抗卵巣がん播種転移薬としての可能性(Group 14 卵巣腫瘍・基礎1,一般演題,公益社団法人日本産科婦人科学会第66回学術講演会)

    北谷 和之, 豊島 将文, 増子 さつき, 重田 昌吾, 石橋 ますみ, 永瀬 智, 八重樫 伸生

    日本産科婦人科學會雜誌　66　(2)　509-509　2014

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  152. 日本人女性における食物摂取と子宮体部類内膜腺癌発症リスクについての症例対照研究

    重田 昌吾, 永瀬 智, 高山 真, 豊島 将文, 宇都宮 裕貴, 菅原 準一, 伊藤 潔, 八重樫 伸生

    北日本産科婦人科学会総会・学術講演会プログラム・抄録集　61回　50-50　2013/09

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  153. 化学療法を先行させた子宮体癌IVB期症例に対する検討

    永井 智之, 永瀬 智, 重田 昌吾, 辻 圭太, 佐藤 いずみ, 田中 創太, 海法 道子, 高野 忠夫, 新倉 仁, 伊藤 潔, 八重樫 伸生

    北日本産科婦人科学会総会・学術講演会プログラム・抄録集　61回　67-67　2013/09

    Publisher: 東北連合産科婦人科学会・北日本産科婦人科学会

  154. 神経症状を呈した成熟奇形腫4例の検討

    永井 智之, 永瀬 智, 重田 昌吾, 辻 圭太, 佐藤 いずみ, 田中 創太, 海法 道子, 高野 忠夫, 新倉 仁, 伊藤 潔, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　31　(3)　471-471　2013/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  155. 当院における婦人科悪性腫瘍脳転移症例の検討

    辻 圭太, 重田 昌吾, 佐藤 いずみ, 永井 智之, 田中 創太, 志賀 尚美, 海法 道子, 豊島 将文, 宇都宮 裕貴, 永瀬 智, 高野 忠夫, 新倉 仁, 伊藤 潔, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　31　(3)　477-477　2013/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  156. 当院で経験した外陰部類上皮肉腫の2症例についての検討

    田中 創太, 佐藤 いずみ, 重田 昌吾, 辻 圭太, 永井 智之, 志賀 尚美, 海法 道子, 豊島 将文, 永瀬 智, 高野 忠夫, 新倉 仁, 伊藤 潔, 八重樫 伸生

    日本婦人科腫瘍学会雑誌　31　(3)　521-521　2013/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  157. 毛芽腫を併発した成熟嚢胞奇形腫を子宮体部類内膜腺癌を合併した一例

    佐藤 いずみ, 永瀬 智, 重田 昌吾, 辻 圭太, 永井 智之, 田中 創太, 海法 道子, 高野 忠夫, 新倉 仁, 八重樫 伸生, 伊藤 潔, 渡辺 みか

    日本婦人科腫瘍学会雑誌　31　(3)　532-532　2013/06

    Publisher: (公社)日本婦人科腫瘍学会

    ISSN： 1347-8559

    eISSN： 2436-8156

  158. セラミドによる細胞移動運動の調節

    北谷 和之, 豊島 将文, 増子 さつき, 重田 昌吾, 石橋 ますみ, 八重樫 伸生

    脂質生化学研究　55　98-98　2013/05/28

    Publisher: 日本脂質生化学会

    ISSN： 0285-1520

  159. ISP-17-4 Identification of Targeted Therapies for Ovarian Cancers by Functional Genomics(Group 17 Oncology 8,IS Poster,International Session) :

    Toyoshima Masafumi, Kitatani Kazuyuki, Mashiko Satsuki, Shigeta Shogo, Yaegashi Nobuo

    65　(2)　1025-1025　2013

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  160. P3-11-9 卵管上皮内癌におけるDNA二本鎖切断とp53発現の免疫組織学的検討(Group 116 卵巣腫瘍・診断・治療(症例)1,一般演題,公益社団法人日本産科婦人科学会第65回学術講演会)

    重田 昌吾, 豊島 将文, 増子 さつき, 北谷 和之, 八重樫 伸生

    日本産科婦人科學會雜誌　65　(2)　887-887　2013

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  161. P3-3-6 卵巣明細胞腺癌におけるPAI-1発現と血栓症発症の関連についての検討(Group 108 卵巣腫瘍・基礎3,一般演題,公益社団法人日本産科婦人科学会第65回学術講演会)

    増子 さつき, 豊島 将文, 北谷 和之, 重田 昌吾, 八重樫 伸生

    日本産科婦人科學會雜誌　65　(2)　865-865　2013

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  162. 既往帝王切開創瘢痕部妊娠後の挙児希望症例に対し腹腔鏡下子宮形成術を施行した一例 Peer-reviewed

    重田 昌吾, 宇賀神 智久, 結城 広光, 八重樫 伸生

    日本産科婦人科内視鏡学会雑誌　28　(1)　353-357　2012/08

    Publisher: (一社)日本産科婦人科内視鏡学会

    ISSN： 1884-9938

    eISSN： 1884-5746

  163. 【婦人科がん-最新の研究動向-】 子宮体がん 子宮平滑筋肉腫の診断と治療 (日本臨床) Invited

    重田昌吾, 永瀬智, 八重樫伸生

    日本臨床　70　(増刊4 婦人科がん)　452-455　2012/06

    Publisher: (株)日本臨床社

    ISSN： 0047-1852

  164. P3-44-2 東日本大震災が津波被災地の周産期医療に与えたインパクト(Group 156 周産期・社会3)

    菅原 準一, 千坂 泰, 星合 哲郎, 佐藤 多代, 宇賀神 智久, 重田 昌吾, 長谷川, 渡辺, 良実, 八重樫 伸生

    日本産科婦人科學會雜誌　64　(2)　878-878　2012

    Publisher: 日本産科婦人科学会

    ISSN： 0300-9165

  165. 【緊急有事における産婦人科体制づくり】 緊急有事における周産期医療システムとその対策 (産婦人科の実際)

    菅原準一, 千坂泰, 宇賀神智久, 星合哲郎, 佐藤多代, 重田昌吾, 長谷川良実, 八重樫伸生

    産婦人科の実際　61　(1)　7-13　2012/01

    Publisher: 金原出版(株)

    ISSN： 0558-4728

  166. 瘢痕部妊娠後の挙児希望症例に対し腹腔鏡下子宮形成術を施行した一例

    重田 昌吾, 宇賀神 智久, 結城 広光

    日本産科婦人科内視鏡学会雑誌　27　(1)　121-121　2011/08

    Publisher: (一社)日本産科婦人科内視鏡学会

    ISSN： 1884-9938

    eISSN： 1884-5746

  167. 産褥期に発生した深部静脈血栓症の1例

    橋本 千明, 重田 昌吾, 永井 智之, 會田 剛史, 河野 順子, 島田 勝子, 菅原 準一

    青森県臨床産婦人科医会誌　24　(1)　27-27　2009/10

    Publisher: 青森県臨床産婦人科医会

    ISSN： 0913-8307

  168. 直腸粘膜下腫瘍で発見された肛門管癌の1例

    高木 祐介, 重田 昌吾, 柏原 彩曜, 越田 真介, 白相 悟, 浅野 重之

    磐城共立病院医報　28　(1)　136-138　2007/09

    Publisher: いわき市医療センター

    ISSN： 0916-3387

Show all ︎Show first 5

Presentations 35

  1. 多角的研究基盤を統合した探索的研究に基づく卵巣明細胞癌の新規個別化医療開発（シンポジウム１ 革新的技術の統合がもたらす婦人科がん治療の未来）

    重田 昌吾

    第76回日本産科婦人科学会学術講演会　2024/04/19

  2. FDAの動物実験義務化撤廃と医学研究における動物実験の代替手段について（ワークショップ 産業と技術革新の基礎をつくろう 分散型臨床試験(DCT: Decentralized clinical trial)) Invited

    重田 昌吾

    第20回 婦人科がん会議　2023/09/09

  3. An attempt by JGOG to develop a new treatment strategy for rare refractory gynecological malignancies

    Shogo Shigeta

    8th APOLLO symposium　2023/08/13

  4. 会長特別企画４：留学の奨め Invited

    重田 昌吾

    第65回 日本婦人科腫瘍学会学術講演会　2023/07/15

  5. 進行・再発卵巣癌維持療法の治療成績と臨床背景に関する後方視的検討（シンポジウム２ 卵巣癌維持療法の日本人リアルワールドデータから見えてくるもの）

    重田 昌吾

    第65回 日本婦人科腫瘍学会学術講演会　2023/07/14

  6. 子宮頸部円錐切除術における術中頸管細胞診の有用性に関する検証

    重田 昌吾

    第61回 日本臨床細胞学会秋期大会　2022/11/05

  7. A comprehensive metabolomic analysis to identify novel therapeutic approach in gynecologic cancer.

    2022/08/05

  8. MicroRNA-152/MMP10 axis regulates endometrial serous carcinoma cell motility

    Shogo Shigeta

    2022/07/15

  9. ブロモドメインを中心とした卵巣明細胞癌に対する新規個別化医療確立に向けた橋渡し研究 （シンポジウム５ 次世代を担う若手医師によるTR）

    重田 昌吾

    第63回日本婦人科腫瘍学会学術講演会　2021/07/18

  10. 術後再発中リスク子宮頸癌IB-IIA期1,657例の臨床病理学的検討

    重田 昌吾

    第73回 日本産科婦人科学会学術講演会　2021/04/23

  11. 婦人科領域の神経内分泌腫瘍に対するVAC-PE交代療法の後方視的検討

    重田 昌吾

    第62回 日本婦人科腫瘍学会学術講演会　2021/01/29

  12. A metabolomic approach to identify novel biomarkers in plasma from ovarian cancer patients

    Shogo Shigeta

    2020/04/23

  13. RNAi及び薬剤スクリーニングを用いた卵巣明細胞癌に対する新規治療標的分子の同定

    重田 昌吾

    第8回 婦人科がんバイオマーカー研究会学術集会　2020/02/08

  14. A clinicopathological analysis of 2,378 patients with FIGO 2018 stage IB1/IB2 cervical cancer by Japanese Gynecologic Oncology Group Network (JGOG 1072s) International-presentation

    Shigeta S

    The 6th biennial meeting of Asian Society of Gynecologic Oncology　2019/10/10

  15. 当院でのロボット支援腹腔鏡下広汎子宮全摘術における卵巣移動の工夫

    重田 昌吾

    第59回 日本産科婦人科内視鏡学会学術講演会　2019/09/12

  16. BET Protein Inhibition in Combination with PI3K-AKT Signal Inhibitors as a Therapeutic Strategy for Clear Cell Carcinoma of the Ovary

    Shigeta S Kemp, C, Grandori C

    2019/07/06

  17. 当院におけるオラパリブ維持療法の使用経験

    重田 昌吾

    第147回日本産科婦人科学会東北連合地方部会　2019/06/16

  18. Targeting Bromodomain Proteins as a Therapeutic Strategy for Clear Cell Carcinoma of the Ovary. International-presentation

    Shogo Shigeta

    12th Rivkin Biennial Ovarian Cancer Research Symposium　2018/09/14

  19. 子宮体がん治療ガイドライン ―検証・問題点・今後―

    重田 昌吾

    第58回日本婦人科腫瘍学会学術講演会　2016/07/08

  20. Transferrin is involved in the carcinogenesis of high-grade serous ovarian cancer by facilitating the DNA double-strand breaks via transferrin receptor 1 in fallopian tube.

    Shigeta S

    2016/04/22

  21. JSOG腫瘍登録データを用いた子宮体がん・卵巣がん治療動向 ー子宮体がんー （JSOG婦人科腫瘍委員会 JSGOガイドライン委員会共同企画）

    重田 昌吾

    第68回日本産科婦人科学会学術講演会　2016/04/22

  22. Transferrin in follicular fluid can facilitate DNA double-strand breaks to fallopian tube epithelium: possible involvement of transferrin in the carcinogenesis of high-grade serous ovarian cancer. International-presentation

    Shigeta S

    2016 annual meeting of the Society of Reproductive Investigation　2016/03/17

  23. 卵巣高グレード漿液性腺癌の発生過程に着目したトランスフェリンとDNA二重鎖切断に関する研究

    重田 昌吾

    第28回がんエピゲノム研究会　2016/01/27

  24. 腹水中に腫瘍細胞が出現した腟悪性黒色腫の一例

    重田 昌吾

    2015/11/22

  25. Transferrin facilitates the formation of DNA-double strand breaks via Transferrin receptor 1 in fallopian tube epithelial cells. International-presentation

    Shigeta S

    AACR advances in ovarian cancer　2015/10/18

  26. 月経血・卵胞液中のトランスフェリン及び卵管上皮細胞のトランスフェリン受容体1の相互作用は卵管上皮細胞におけるＤＮＡ２重鎖切断を増幅させる。

    重田 昌吾

    第67回日本産科婦人科学会学術講演会　2015/04/10

  27. Transferrin induces and amplifies DNA-double strand breaks via Transferrin receptor 1 in human fallopian tubal epithelial cell model.

    Shigeta S

    2015 annual meeting of Society of Reproductive Investigation　2015/03/26

  28. 日本人女性における食物摂取と子宮体部類内膜腺癌発症リスクについての症例対照研究

    重田 昌吾, 永瀬, 智, 高山, 真, 豊島, 将文, 宇都宮, 裕貴, 菅原, 準一, 伊藤, 潔, 八重樫, 伸

    第61回北日本産科婦人科学会学術講演会　2013/09/07

  29. 卵管上皮内腺癌におけるDNA二本鎖切断とp53発現の免疫組織学的検討

    重田 昌吾

    第65回日本産科婦人科学会学術講演会　2013/05/12

  30. Epidemiology of the Human Papilloma Virus, and the Present State of Vaccination/Cancer Screening in Japan

    Shigeta S, Masuda K, Mitsui H, Matsuzaki S, Kawamura K

    2013/05/10

  31. Identification of novel estrogen receptor α target gene and its function in endometrial cancer International-presentation Invited

    Shigeta S, Utsunomiya H

    Annual clinical meeting of The American Congress of obstetricians and gynecologists　2012/05/05

  32. 既往帝王切開創瘢痕部妊娠後の挙児希望症例に対し腹腔鏡下子宮形成術を施行した一例

    重田 昌吾, 宇賀神, 智久, 結城 広光

    第51回日本産科婦人科内視鏡学会学術講演会　2011/08/06

  33. 当院での単孔式による腹腔鏡下手術症例の検討

    重田 昌吾, 宇賀神, 智久

    第131回日本産科婦人科学会 東北連合地方部会　2011/06/05

  34. 当院における切迫早産症例に対する塩酸リトドリン投与についての後方視的検討

    重田 昌吾

    第129回日本産科婦人科学会 東北連合地方部会　2010/05/23

  35. 帝王切開術後に産褥心筋症を発症した双胎妊娠の一例

    重田 昌吾

    第127回日本産科婦人科学会 東北連合地方部会　2009/06/06

Show all Show first 5

Research Projects 9

  1. フェロミクス解析を用いた褥瘡形成における鉄の病態生理学的役割の解明

    西田 健太朗, 北谷 和之, 重田 昌吾

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業

    Category: 基盤研究(C)

    Institution: 摂南大学

    2024/04/01 - 2028/03/31

  2. 上皮性卵巣癌におけるネクロプトーシスの臨床的意義と治療標的としての可能性

    橋本 千明, 石橋 ますみ, 重田 昌吾, 北谷 和之

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業

    Category: 基盤研究(C)

    Institution: 東北大学

    2024/04/01 - 2027/03/31

  3. A multi-omics investigation of novel therapeutic strategies for clear cell carcinoma of the ovary focusing on cancer metabolism

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research

    Category: Grant-in-Aid for Scientific Research (C)

    Institution: Tohoku University

    2023/04/01 - 2026/03/31

  4. ネクロプトーシスの脂質性制御とセラミド分子認識の解明

    北谷 和之, 伊藤 潔, 重田 昌吾

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業

    Category: 基盤研究(C)

    Institution: 摂南大学

    2022/04/01 - 2025/03/31

  5. 難治性卵巣粘液性癌に対する新たな治療戦略の開発

    島田 宗昭, 徳永 英樹, 重田 昌吾

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業

    Category: 基盤研究(C)

    Institution: 東北大学

    2021/04/01 - 2024/03/31

    More details Close

    本研究の対象疾患である難治性希少癌である卵巣粘液性癌のゲノム解析を開始した。婦人科がんに対するメタボローム解析の意義を検証する研究の結果、卵巣がんに対する診断、化学療法感受性・予後の予測、治療標的の同定などに有用であることを報告した（Hishinuma E, Shimada M. Wide-targeted metabolome analysis identifies potential biomarkers for prognosis prediction of epithelial ovarian cancer. 2021. Toxins）。 この結果を踏まえて、ゲノム解析を進めつつ、メタボローム解析を加えた多層的オミックス解析により本研究対象である難治性希少癌である卵巣粘液性癌に対する新規治療標的の開発、治療効果・予後予測などの予測医療をより実現化するためにメタボローム解析を加えることとし、本研究対象を含めた卵巣がん検体350例のメタボローム解析を行った。現在、卵巣癌の検体を組織型別、進行期別などの解析を進めており、卵巣粘液性癌に対する診断、化学療法感受性・予後を予測するメタボロームプロファイルの解析結果が期待される。 卵巣粘液性癌のゲノム解析を施設内で行える体制整備が完了したため、検体集積に努めつつ、卵巣粘液性癌のゲノム解析を進めて、ゲノム解析とメタボローム解析との統合解析を令和４年度の目標とする。

  6. 予後不良卵巣癌における薬剤製剤抵抗性の機序解明と新規治療標的の開発

    徳永 英樹, 島田 宗昭, 重田 昌吾

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業

    Category: 基盤研究(C)

    Institution: 東北大学

    2021/04/01 - 2024/03/31

    More details Close

    ZFHX4,CHD4によるがん幹細胞化の維持、プラチナ感受性制御機構の解明 CHD4 mRNAの発現は卵巣がん患者由来の組織を用いた検討で、白金製剤耐性群で有意に高かった。CHD4の過剰発現が卵巣がん細胞に白金製剤耐性を誘導し、生存予後を低下させることが示唆された。CHD4のノックダウンは、卵巣がん細胞株TOV21Gにおいてシスプラチンを介したアポトーシスを誘導した。ところが、CHD4のノックダウンは、RAD51やp21（他のがん種でCHD4の標的として知られ、プラチナ感受性を調節する）の発現には影響を与えなかった。また、CHD4は、MDR1の発現を正に制御していることが、ノックダウンおよび過剰発現実験により明らかになった。並行して、CHD4阻害剤の効果を二次元培養系で検証し、ノックダウンの系と同様の知見を得た。卵巣がん患者由来の血漿中の代謝物を超高速液体クロマトグラフ-タンデム質量分析計（UHPLC-MS/MS）を用いて解析した結果、トリプトファンに対するキヌレニンの比率が高いほど、予後不良であった。血漿メタボローム解析が予後予測や化学療法への反応性評価にも有用であることがわかった。In vivoモデルにおいても細胞内および培養液中の代謝物のプロファイルを測定できるよう計画に加えることとした。 二次元培養モデルから三次元培養モデルへの移行のため、細胞株および卵巣がん患者組織由来のオルガノイドの系を複数樹立するため、培養条件の検討を継続している。

  7. Targeting epigenetic regulators as a novel combination therapy for gynecologic malignancies harboring SWI/SNF alteration.

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research

    Category: Grant-in-Aid for Early-Career Scientists

    Institution: Tohoku University

    2020/04/01 - 2023/03/31

  8. 腹膜播種オルガノイドモデルを用いたプラチナ耐性卵巣癌に対する新規治療法の開発

    辻 圭太, 島田 宗昭, 徳永 英樹, 重田 昌吾

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業

    Category: 基盤研究(C)

    Institution: 東北大学

    2019/04/01 - 2023/03/31

    More details Close

    令和２年度までの研究で、RNA干渉法やin silicoの解析を通して卵巣癌のプラチナ感受性を制御する分子としてChromodomain-helicase-DNA-binding protein 4 (CHD4)を同定した。加えてCHD4が多剤耐性トランスポーターであるP糖タンパク質をコードする遺伝子であるMDR1発現を正に調節する可能性を見出し、複数の卵巣癌細胞においてCHD4の発現抑制によりP糖タンパク質の発現が減弱すること、逆にCHD4発現ベクターを用いた過剰発現実験によりP糖タンパク質の発現が増強することを証明した。P糖タンパク質は薬剤の細胞外排出を介してプラチナ抵抗性に関わる分子であることが複数の研究ですでに示されており、本研究結果からはCHD4がMDR1/P糖タンパク質の発現を介して卵巣癌のプラチナ感受性を制御していることが示された。 また、臨床検体を用いた研究でプラチナ抵抗性症例においてCHD4の発現が高いことを確認した。細胞株のみならず生体中の卵巣癌においてもやはりCHD4がプラチナ感受性を制御している可能性があることが示された。 さらに、海外の研究者が同定した新規CHD4阻害剤の提供をうけ同阻害剤の添加によってプラチナ抵抗性卵巣癌細胞株においてプラチナ感受性が増強することを実験的に証明した。 現時点で生体投与の安全性が証明されたCHD4阻害剤は存在しないが、本研究結果からは臨床においてCHD4阻害剤とプラチナ製剤の併用療法が期待されるとともに、生体利用率が高く、かつ安全性が担保されたCHD4阻害剤開発の必要性が示唆される。また、より生体の腫瘍に近い性質を持った実験モデルである癌オルガノイドを用いてCHD4阻害剤、プラチナ製剤併用療法の有効性についての検証実験も行うべく予備実験を進めているところであり、次年度も継続する予定である。

  9. Targeting bromodomains as a novel therapeutic strategy for clear cell carcinoma of the ovary.

    Shigeta Shogo

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research

    Category: Grant-in-Aid for Research Activity Start-up

    Institution: Tohoku University

    2019/08/30 - 2021/03/31

    More details Close

    Focusing on epigenomic regulators, we investigate therapeutic target candidates for clear cell carcinoma of the ovary (OCCC), one of the chemo-resistant subtypes in ovarian cancer. It was elucidated that functional interference of BET proteins BRD2/BRD3 strongly suppresses OCCC cell proliferation. We also identified several inhibitors which synergistically suppress OCCC cell growth in combination with BET inhibitors. It was also revealed that the suppression of the function of CHD4 sensitizes OCCC cells to platinum agents, a key anti-cancer drug in the treatment of ovarian cancer. In this study, we also attempted to develop OCCC organoids that recapitulate drug sensitivity of their original tumor. We were successful in short-term OCCC organoid maintenance. The synergistic drug interactions detected in this study is to be examined in organoid model after the optimization of the culture protocol for long-term stable maintenance.

Show all Show first 5

Social Activities 3

  1. カトレアの森 茶話会

    2023/08/17 - 2023/08/17

  2. カトレアの森 茶話会

    茶話会

    2019/05/16 - 2019/05/16

  3. カトレアの森 茶話会

    茶話会

    2015/06/18 - 2015/06/18